Heteroaryl compounds for treatment of pain

Abstract

Compounds and pharmaceutically acceptable salts thereof useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or the pharmaceutically acceptable salts, and methods of using the compounds, the pharmaceutically acceptable salts, and the pharmaceutical compositions in the treatment of various conditions, including pain.

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 333,873, filed April 22, 2022, which is incorporated herein by reference in its entirety. Background Art

[0003] Pain is a protective mechanism that allows healthy animals to avoid tissue damage and prevent further damage to injured tissue. Nevertheless, in many cases, pain persists beyond its scope of action, or patients benefit from pain suppression. Neuropathic pain is a form of chronic pain caused by sensory nerve damage (Dieleman, JP et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain, 2008.137 (3): p. 681-8). Neuropathic pain can be divided into two categories: pain caused by systemic metabolic damage to nerves and pain caused by discrete nerve damage. Metabolic neuropathy includes post-herpetic neuropathy, diabetic neuropathy and drug-induced neuropathy. Discrete nerve injury indications include post-amputation pain, postoperative nerve injury pain and nerve entrapment injury such as neuropathic back pain.

[0004] Voltage-gated sodium channels (Na V ) is involved in pain signal transduction. V Sodium channels are biological mediators of electrical signaling because they mediate the rapid rise of the action potential in many excitable cell types (e.g., neurons, skeletal muscle cells, and cardiac myocytes). Evidence for the role of these channels in normal physiology, pathological conditions caused by mutations in sodium channel genes, preclinical work in animal models, and clinical pharmacology of known sodium channel modulators all point to the role of sodium channels in normal physiology. V Central role in pain perception (Rush, AM and TR Cummins, Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets Na V1.8 Sodium Channels. Mol. Interv., 2007. 7(4): p. 192-5); England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin. Investig. Drugs 17(12), p. 1849-64 (2008); Krafte, DS and Bannon, AW, Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr. Opin. Pharmacol. 8(1), p. 50-56 (2008). Na V Mediates the rapid rise of the action potential of many excitable cell types (e.g., neurons, skeletal muscle cells, cardiac muscle cells) and is therefore involved in the initiation of signal transduction in those cells (Hille, Bertil, Ion Channels of Excitable Membranes, 3rd ed. (Sinauer Associates, Inc., Sunderland, MA, 2001)). V Role in the initiation and propagation of neuronal signals, reducing Na V Antagonists of this current can prevent or reduce nerve signaling, and it has been suggested that Na V Channels are possible targets for reducing pain in situations where hyperexcitability is observed (Chahine, M., Chatelier, A., Babich, O., and Krupp, JJ, Voltage-gated sodium channels in neurological disorders. CNS Neurol. Disord. Drug Targets 7(2), pp. 144-58 (2008)). Several clinically useful analgesics have been identified as Na V Channel inhibitors. VChannel-blocking pain local anesthetics such as lidocaine and other compounds that have been shown to be effective in reducing pain such as carbamazepine, lamotrigine, and tricyclic antidepressants have also been suggested to act through sodium channel inhibition (Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action. Eur. J. Pain, 6 Suppl. A, pp. 3-9 (2002); Wang, GK, Mitchell, J. and Wang, SY, Block of persistent late Na+ current by the antidepressants sertraline and paroxetine. + currents by antidepressant sertraline and paroxetine). Journal of Membrane Biology (J. Membr. Biol.), 222(2), pp. 79-90 (2008).

[0005] Na V Forms a subfamily of the voltage-gated ion channel superfamily and includes nine isoforms named Na V 1.1-Na V 1.9. These nine subtypes have different tissue localizations. V 1.4 is the main sodium channel in skeletal muscle, and Na V 1.5 is the main sodium channel in myocardial cells. V 1.7, 1.8 and 1.9 are mainly located in the peripheral nervous system, while Na V 1.1, 1.2, 1.3 and 1.6 are neuronal channels found in both the central and peripheral nervous systems. The nine subtypes have similar functional behaviors but differ in the characteristics of voltage dependence and kinetic behavior (Catterall, WA, Goldin, AL and Waxman, SG, International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57(4), p. 397 (2005)).

[0006] After its discovery, Na V1.8 channel was identified as a possible analgesic target (Akopian, AN, L. Sivilotti and JN Wood, Atetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996. 379(6562): p. 257-62). V 1.8 has been shown to be a carrier of sodium current that sustains action potential discharge in small dorsal root ganglion (DRG) neurons (Blair, NT and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na + current,TTX-resistant Na + current,andCa 2+ current in the action potentials of nociceptive sensoryneurons. J. Neurosci., 2002.22(23): pp. 10277-90). Na V 1.8 is involved in spontaneous firing in damaged neurons, such as those that drive neuropathic pain (Roza, C. et al., The tetrodotoxin-resistant Na + channel Na V 1.8 is essential for the expression of spontaneous activity indamaged sensory axons of mice. J. Physiol., 2003.550 (Pt 3): Page 921-6; Jarvis, MF et al., A-803467, a potent and selective Na V 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. USA, 2007.104(20): Page 8520-5; Joshi, SK et al., Involvement of the TTX-resistant sodium channel Na V1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain, 2006. 123(1-2): pp. 75-82; Lai, J. et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Na V 1.8. Pain, 2002. 95(1-2): pp. 143-52; Dong, X.W. et al., Small interfering RNA-mediated selective knockdown of Na V1.8 tetrodotoxin-resistant sodium channelreverses mechanical allodynia in neuropathic rats. Neuroscience, 2007.146(2): pages 812-21; Huang, HL et al.; Proteomic profiling of neuromas reveals alterationsin protein composition and local protein synthesis in hyper-excitablenerves. Mol. Pain, 2008.4: Page 33; Black, JA et al., Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful humanneuromas. Ann. Neurol., 2008.64(6): Page 644-53; Coward, K. et al., Immunolocalization of SNS / PN3 and NaN / SNS2 sodium channels in human pain states. Pain, 2000.85(1-2): pages 41-50; Yiangou, Y. et al., SNS / PN3 and SNS2 / NaN Sodium channel-likeimmunoreactivity in human adult and neonate injured sensory nerves. FEBS Lett., 2000.467(2-3): Pages 249-52; Ruangsri, S. et al., Relationship of axonalvoltage-gated sodium channel 1.8 (Na V 1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats. J. Biol. Chem. 286(46): p. 39836-47). Expression of Na V The small DRG neurons of 1.8 include nociceptors involved in pain signaling. V1.8 Mediating large-amplitude action potentials in small neurons of the dorsal root ganglion (Blair, NT and BPBean, Roles of tetrodotoxin (TTX)-sensitive Na + current,TTX-resistant Na + current, and Ca 2+ current in the actionpotentials of nociceptive sensory neurons. J. Neurosci., 2002.22(23): pp. 10277-90). Na V 1.8 is required for rapid repetitive action potentials in nociceptors and spontaneous activity in injured neurons. (Choi, JS and SG Wixman, Physiological interactions between Na V 1.7 and Na V 1.8 sodiumchannels: a computer simulation study.J.Neurophysiol.106(6): pages 3173-84; Renganathan, M., TRCummins and SGWaxman, Contribution of Na( V )1.8sodiumchannels to action potential electrogenesis in DRG neurons.J.Neurophysiol., 2001.86(2): pp. 629-40; Roza, C. et al., The tetrodotoxin-resistant Na + channel Na V 1.8 is essential for the expression of spontaneous activity in damaged sensoryaxons of mice. J. Physiol., 2003. 550(Pt3): p. 921-6). In depolarized or damaged DRG neurons, Na V1.8 appears to be a driving factor for hyperexcitability (Rush, AM et al., A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA, 2006. 103(21): p. 8245-50). In some animal pain models, it has been shown that Na in DRG V 1.8 mRNA expression levels increased (Sun, W. et al., Reduced conduction failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats. Brain, 135(Part 2): 359-75; Strickland, IT et al., Changes in the expression of Na V 1.7,Na V 1.8 and Na V 1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur.J.Pain, 2008.12(5): pp. 564-72; Qiu, F. et al., Increased expression of tetrodotoxin-resistant sodium channels Na V 1.8 andNa V 1.9 within dorsal root ganglia in a rat model of bone cancerpain. Neurosci. Lett., 512(2): pp. 61-6).

[0007] The present inventors have found that, due to, for example, a poor therapeutic window (e.g., due to lack of Na V Some voltage-gated sodium channel inhibitors have limitations as therapeutic agents due to isotype selectivity, low potency, and / or other reasons. Therefore, there is still a need to develop selective voltage-gated sodium channel inhibitors, such as selective Na V1.8 Inhibitors. Summary of the Invention

[0008] In one aspect, the present invention relates to a compound described herein or a pharmaceutically acceptable salt thereof.

[0009] In another aspect, the present invention relates to a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or vehicles.

[0010] In yet another aspect, the invention relates to a method of inhibiting a voltage-gated sodium channel in a subject by administering to the subject the compound, pharmaceutically acceptable salt or pharmaceutical composition.

[0011] In yet another aspect, the present invention relates to a method of treating or lessening the severity of various diseases, disorders or conditions in a subject by administering to the subject the compound, pharmaceutically acceptable salt or pharmaceutical composition, including but not limited to chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., bunionectomy pain, hernia repair pain or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough and arrhythmia. DETAILED DESCRIPTION

[0012] In one aspect, the present invention relates to a compound of formula (I):

[0013]

[0014] or a pharmaceutically acceptable salt thereof, wherein:

[0015] X 5a N, N + -O - or N + -CH3;

[0016] X 9a N or CR 9a ;

[0017] R 3ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0018] R 4a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0019] R 6ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0020] R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0021] Each R a' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0022] Y is

[0023] X 2b N or CR 2b ;

[0024] X 3b N or CR 3b ;

[0025] X 4b N or CR 4b ;

[0026] X 5b N or CR 5b ;

[0027] X 6b N or CR 6b ;

[0028] Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring;

[0029] R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C( O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0030] R 3bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0031] R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), 3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace;

[0032] R 5bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0033] R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0034] R 7b is a C1-C6 alkyl group;

[0035] R 9b is a C1-C6 alkyl group;

[0036] R 10b is H or halogen;

[0037] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and

[0038] R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH;

[0039] The conditions are:

[0040] (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than three of them are H; and

[0041] (ii) If Y is X 3b is N, and X 6b CR 6b , then R 2b 、R 4b 、R 5b and R 6b No more than three of them are H; and

[0042] (iii) If Y is X 3b CR 3b , and X 6b is N, then R 2b 、R 3b 、R 4b and R 5b No more than three of them are H; and

[0043] (iv) If X 9a N is N, Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than two of are halo; and

[0044] (v) If X 9a N is N, Y is X 4b CR 4b , X 5b CR 5b , and X 6b CR 6b ,but:

[0045] R 4b 、R 5b and R 6bNo more than two of them are H; or

[0046] Z is replaced by one or more R z replace.

[0047] In another aspect, the present invention relates to a compound of formula (II):

[0048]

[0049] or a pharmaceutically acceptable salt thereof, wherein:

[0050] R 3c is H, halogen or C1-C6 alkyl;

[0051] R 4c is H, halogen, -CN or C1-C6 alkoxy;

[0052] R 5c is H, halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or -C(O)O(C1-C6 alkyl);

[0053] R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen;

[0054] R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl);

[0055] Y is

[0056] X 3d N or CR 3d ;

[0057] R 2d 、R 3d and R 4d The definition is as follows:

[0058] (i)R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH;

[0059] R 3d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; and

[0060] R 4dis H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or

[0061] (ii)R 2d and R 3d Together with the carbon atoms to which they are attached, they form a ring of the formula:

[0062] and

[0063] R 4d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or

[0064] (iii)R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -(C1-C6 alkylene)-OH; and

[0065] R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula:

[0066]

[0067] R 5d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or -C(O)(C1-C6 alkyl);

[0068] R6d is H, halogen or C1-C6 alkyl;

[0069] R 7d is a C1-C6 alkyl group; and

[0070] R 9d is a C1-C6 alkyl group;

[0071] The conditions are:

[0072] (i) If Y' is And X 3d CR 3d , then R 2d 、R 3d 、R 4d 、R 5d and R 6d No more than four of them are H; and

[0073] (ii) If Y' is And X 3d is N, then R 2d 、R 4d 、R 5d and R 6d No more than three of them are H.

[0074] In another aspect, the present invention relates to a compound of formula (III):

[0075]

[0076] or a pharmaceutically acceptable salt thereof, wherein:

[0077] X 3k N or CH;

[0078] X 4k N or CH;

[0079] X 5k N or CR 5k ;

[0080] X 6k N, N + -O - or CR 6k ;

[0081] R 5k is H, C1-C6 alkoxy, -OH, -OCH2CH2N(CH3)2 or -N(CH3)(CH2CH2OCH3);

[0082] R 6k is H, -OH, C1-C6 alkoxy or -C(O)NH2;

[0083] R 2L is a C1-C6 alkyl group;

[0084] R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-; and

[0085] R 5L is H, halogen or C1-C6 alkyl,

[0086] The conditions are:

[0087] (i)X 3k 、X 4k and X 5k At least one of them is N, or X 6k N or N + -O - ;and

[0088] (ii)X 3k 、X 4k 、X 5k and X 6k No more than two of them are N; and

[0089] (iii) If X 6k N + -O - , then X 3k and X 4k is CH, and X 5k CR 5k ;and

[0090] (iv) If X 5k is N, then X 4k is N.

[0091] For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed. In addition, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5th ed., eds.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.

[0092] As used herein, the term "compound of the present invention" refers to compounds of Formula (I), (II), and (III) as described herein, and all embodiments thereof (e.g., Formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (II-A), (II-B), (II-C), (III-A), etc.), as well as the compounds identified in Table A and Table B.

[0093] As described herein, the compounds of the present invention include a number of variable groups (e.g., X 5a 、R 4a , Y, Z, etc.). As will be appreciated by one of ordinary skill in the art, the combinations of groups contemplated by the present invention are those that result in the formation of stable or chemically feasible compounds. In this context, the term "stable" refers to compounds that do not undergo substantial change when subjected to conditions that allow them to be produced, detected, and preferably recovered, purified, and used for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that does not undergo substantial change when stored at 40°C or less in the absence of moisture or other chemically reactive conditions for at least one week.

[0094] The chemical structures depicted herein are intended to be understood as chemical structures that would be understood by one of ordinary skill in the art. For example, with respect to formula (III) and (III-A), X 6k and X 5k Connected by a double bond, and X 5k and X 4kThe groups are connected by single bonds, even though the bonds between these groups may be obscured by the labeling of atoms in the chemical structure. Additionally, a substituent depicted in a chemical structure as "CF3" or "F3C" is a trifluoromethyl substituent, whichever depiction appears in the chemical structure.

[0095] As used herein, the term "halo" refers to F, Cl, Br, or I.

[0096] As used herein, the term "alkyl" refers to a straight or branched hydrocarbon chain radical radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having a specified number of carbon atoms attached to the remainder of the molecule by a single bond. For example, a "C1-C6 alkyl" is an alkyl group having from one to six carbon atoms.

[0097] As used herein, the term "alkenyl" refers to a straight or branched hydrocarbon chain radical radical consisting solely of carbon and hydrogen atoms, containing one or more carbon-carbon double bonds and having a specified number of carbon atoms attached to the remainder of the molecule by a single bond. For example, "C2-C6 alkenyl" is an alkenyl group having from two to six carbon atoms.

[0098] As used herein, the term "cycloalkyl" refers to a stable, non-aromatic, monocyclic or bicyclic (fused, bridged or spirocyclic) saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, having the specified number of carbon atoms and attached to the remainder of the molecule by a single bond. For example, a "C3-C8 alkyl" is a cycloalkyl radical having three to eight carbon atoms.

[0099] As used herein, the term "alkoxy" refers to -OR a The free radical, R a is an alkyl group having the specified number of carbon atoms. For example, "C1-C6 alkoxy" is of the formula -OR a A group in which R a is an alkyl group having one to six carbon atoms.

[0100] As used herein, the term "haloalkyl" refers to an alkyl group having a specified number of carbon atoms, wherein one or more of the alkyl group's hydrogen atoms are replaced by a halo group. For example, a "C1-C6 haloalkyl" is an alkyl group having from one to six carbon atoms, wherein one or more of the alkyl group's hydrogen atoms are replaced by a halo group.

[0101] As used herein, the term "haloalkenyl" refers to an alkenyl group having a specified number of carbon atoms, wherein one or more of the hydrogen atoms of the alkenyl group are replaced by a halo group. For example, a "C1-C6 haloalkenyl" is an alkenyl group having from one to six carbon atoms, wherein one or more of the hydrogen atoms of the alkenyl group are replaced by a halo group.

[0102] As used herein, the term "haloalkoxy" refers to an alkoxy group having the specified number of carbon atoms in which one or more of the hydrogen atoms of the alkyl group are replaced by a halo group.

[0103] As used herein, the term "alkylene" refers to a divalent straight or branched hydrocarbon chain radical radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having a specified number of carbon atoms connected to the remainder of the molecule by two single bonds. For example, "C1-C6 alkylene" is an alkylene radical having from one to six carbon atoms.

[0104] As used herein, the term "alkenylene" refers to a divalent straight or branched hydrocarbon chain radical radical consisting solely of carbon and hydrogen atoms, containing one or more carbon-carbon double bonds and having a specified number of carbon atoms connected to the rest of the molecule by two single bonds. For example, "C2-C6 alkenylene" is an alkenylene radical having from one to six carbon atoms.

[0105] As used herein, the term "haloalkylene" refers to an alkylene group having a specified number of carbon atoms, wherein one or more of the hydrogen atoms of the alkylene group are replaced by a halo group. For example, a "C1-C6 haloalkylene group" is an alkylene group having one to six carbon atoms, wherein one or more of the hydrogen atoms of the alkylene group are replaced by a halo group.

[0106] As used herein, the term "heterocyclic radical" refers to a stable, non-aromatic, monocyclic, bicyclic or tricyclic (fused, bridged or spirocyclic) group, wherein one or more ring atoms are heteroatoms (e.g., heteroatoms independently selected from N, O, P and S), which have a specified number of ring atoms and are connected to the rest of the molecule by a single bond. The heterocycle can be saturated or can contain one or more double or triple bonds. In certain embodiments, a "heterocyclic radical" has an indicated number of ring members, wherein one or more ring members are heteroatoms independently selected from oxygen, sulphur, nitrogen and phosphorus, and each ring in the ring system contains 3 to 7 ring members. For example, a 6-membered heterocyclic radical comprises a total of 6 ring members, at least one of which is a heteroatom (e.g., heteroatoms independently selected from N, O, P and S).

[0107] As used herein, the term "heteroaryl" refers to a stable monocyclic, bicyclic or tricyclic ring group having a specified number of ring atoms, wherein at least one ring in the system is aromatic, and at least one aromatic ring in the system contains one or more heteroatoms (e.g., one or more heteroatoms independently selected from N, O, P and S). In some embodiments, each ring in the system contains 3 to 7 ring members. For example, a 6-membered heteroaryl group contains a total of 6 ring members, at least one of which is a heteroatom selected from N, S, O and P. The term "heteroaryl" can be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".

[0108] As used herein, as shown in the following structures, the labels "*2" and "*3" designate the corresponding R groups (in this case, R 2d and R 3d The carbon atom to which the group is attached:

[0109]

[0110] Similarly, the "*3" and "*4" in the following structure specify R 3d and R 4d The carbon atom to which the group is attached:

[0111]

[0112] Unless otherwise indicated, the compounds of the present invention, whether identified by chemical name or chemical structure, encompass all stereoisomers (e.g., enantiomers and diastereomers), double bond isomers (e.g., (Z) and (E)), conformers, and tautomers of the compounds identified by the chemical names and chemical structures provided herein. In addition, single stereoisomers, double bond isomers, conformers, and tautomers, as well as mixtures of stereoisomers, double bond isomers, conformers, and tautomers, are within the scope of the present invention.

[0113] As used herein, in any chemical structure or formula, a non-bold direct bond to a stereogenic center of a compound, such as in

[0114]

[0115] Indicates that the configuration of a stereocenter is unspecified. A compound may have any configuration or mixture of configurations at a stereocenter.

[0116] As used herein, the prefix "rac-" when used in conjunction with a chiral compound refers to a racemic mixture of the compound.

[0117] As used herein, the prefix "rel-" when used in conjunction with a chiral compound refers to a single enantiomer of unknown absolute configuration. In compounds bearing the "rel-" prefix, the (R)- and (S)-designators in the chemical name reflect the relative stereochemistry of the compound, but not necessarily the absolute stereochemistry of the compound. In cases where the relative stereochemistry of a given stereocenter is unknown, no stereochemical designator is provided.

[0118] As used herein, the term "compound" when referring to a compound of the present invention refers to a collection of molecules having the same chemical structure, except that there may be isotopic variations between the constituent atoms of the molecules. The term "compound" encompasses such a collection of molecules without regard to the purity of a given sample containing the collection of molecules. Thus, the term "compound" encompasses a collection of molecules in pure form, in a mixture with one or more other substances (e.g., a solution, suspension, colloid, or pharmaceutical composition or dosage form), or in the form of a hydrate, solvate, or co-crystal.

[0119] In the specification and claims, unless otherwise indicated, any atom in any compound of the present invention that is not specifically designated as a particular isotope is intended to represent any stable isotope of the specified element. In examples, where an atom in any compound of the present invention is not specifically designated as a particular isotope, no effort has been made to enrich such atom in that particular isotope, and thus, one of ordinary skill in the art will understand that such atom is likely to be present at approximately the natural abundance isotopic composition of the specified element.

[0120] As used herein, the term "stable" when referring to an isotope means that the isotope is not currently known to undergo spontaneous radioactive decay. Stable isotopes include, but are not limited to, isotopes for which the decay mode is undefined in: VS Shirley and CM Lederer, Isotope Project, Nuclear Science Division, Lawrence Berkeley Laboratory, Table of Nuclides (January 1980).

[0121] As used in this specification and claims, "H" means hydrogen and includes any stable isotope of hydrogen, i.e. 1 H and D. In instances where an atom is designated as "H," no effort has been made to enrich such atom in a particular isotope of hydrogen, and thus one of ordinary skill in the art will understand that such hydrogen atom is likely to be present at about the natural abundance isotopic composition of hydrogen.

[0122] As used herein, “ 1 H" refers to protium. Where an atom in a compound of the invention or a pharmaceutically acceptable salt thereof is designated as protium, the protium is present at the designated position at a concentration of at least the natural abundance of protium.

[0123] As used herein, "D", "d" and " 2 H” refers to deuterium.

[0124] In some embodiments, the compounds of the present invention and pharmaceutically acceptable salts thereof contain for each constituent atom approximately the natural abundance isotopic composition of a designated element.

[0125] In some embodiments, the compounds of the present invention and pharmaceutically acceptable salts thereof contain one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the most abundant isotope of a specified element ("isotopically labeled" compounds and salts). Examples of commercially available stable isotopes suitable for the present invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, and phosphorus, for example, 2 H. 13 C. 15 N. 18 O. 17 O and 31 P.

[0126] Isotope-labeled compounds and salts can be used in a variety of beneficial ways, including as pharmaceuticals. In some embodiments, isotope-labeled compounds and salts are deuterated ( 2 H) labeling. Deuterium ( 2 H) The labeled compounds and salts are therapeutically useful and compared to non 2 H-labeled compounds have potential therapeutic advantages. In general, deuterium ( 2 H) labeled compounds and salts can have higher metabolic stability due to the kinetic isotope effect described below. Higher metabolic stability directly translates into increased half-life in vivo or lower dosage, which in most cases will represent preferred embodiments of the present invention. Isotope-labeled compounds and salts can generally be prepared by carrying out the procedures disclosed in the synthetic schemes, examples, and related descriptions, substituting non-isotope-labeled reactants with readily available isotope-labeled reactants.

[0127] deuterium( 2 H) labeled compounds and salts can manipulate the oxidative metabolic rate of a compound through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction caused by the exchange of isotopic nuclei, which in turn is caused by a change in the ground state energy of the covalent bonds involved in the reaction. The exchange of heavier isotopes generally results in a decrease in the ground state energy of a chemical bond, and therefore in a reduction in rate-limiting bond breakage. If bond breakage occurs in or near a saddle point region along the coordinates of a multi-product reaction, the product distribution ratio may change significantly. For example, if deuterium is bonded to a carbon atom at a non-exchangeable position, then k H / kD Rate differences of 2-7 are typical. For further discussion, see SL Harbeson and RD Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417, which is incorporated herein by reference in its entirety.

[0128] The concentration of an isotope (e.g., deuterium) incorporated at a given position of an isotopically labeled compound of the invention, or a pharmaceutically acceptable salt thereof, can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" refers to the ratio between the abundance of an isotope at a given position in an isotopically labeled compound (or salt) and the natural abundance of the isotope.

[0129] Where an atom in a compound of the invention or a pharmaceutically acceptable salt thereof is designated as deuterium, such compound (or salt) has an isotopic enrichment factor with respect to such atom of at least 3000 (approximately 45% deuterium incorporation). In some embodiments, the isotopic enrichment factor is at least 3500 (about 52.5% deuterium incorporation), at least 4000 (about 60% deuterium incorporation), at least 4500 (about 67.5% deuterium incorporation), at least 5000 (about 75% deuterium incorporation), at least 5500 (about 82.5% deuterium incorporation), at least 6000 (about 90% deuterium incorporation), at least 6333.3 (about 95% deuterium incorporation), at least 6466.7 (about 97% deuterium incorporation), at least 6600 (about 99% deuterium incorporation), or at least 6633.3 (about 99.5% deuterium incorporation).

[0130] In some embodiments, the present invention relates to a compound of formula (I), wherein:

[0131] R 6ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0132] Y is

[0133] R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0134] R 4bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

[0135] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5a is N. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -CH3.

[0136] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a In some embodiments, the present invention relates to a compound of formula (I), wherein X 9a CR 9a And R 9a is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -C(O)OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a And R 9a is H, halogen, C1-C6 alkyl or C1-C6 alkoxy. 9a In other embodiments, R 9a is a C1-C6 alkyl group. In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R 9a In other embodiments, R 9aIn some embodiments, the present invention relates to a compound of formula (I), R 9a is H, Cl, Br, -CH3, -OCH3, -OCH2CH3, -C(O)OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a And R 9a is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a It is -C(O)OCH3.

[0137] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3a In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3a In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3a is H. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3a is -CH3.

[0138] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4a For H.

[0139] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 6ais H, -CN, C1-C6 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is independently Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C6 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is C1-C6 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)O(C1-C6 alkyl). In other embodiments, R 6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is independently Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 6a For H, -CN, -OCH3, -OCH2CH2CH(CH3)2, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OC H2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2,

[0140]

[0141]

[0142] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 6a In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2CH(CH3)2. In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6ais -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)N(CH3)2. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -C(S)NH2. In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0143] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is

[0144] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3b is N. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, C1-C6 alkyl or C1-C6 haloalkyl. 3b is a C1-C6 alkyl group. In other embodiments, R 3b is a C1-C6 haloalkyl group. In other embodiments, R 3bIn some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, -CH3 or -CF3. In other embodiments, R 3b is H. In other embodiments, R 3b In other embodiments, R 3b In other embodiments, R 3b is D. In other embodiments, R 3b In other embodiments, R 3b For F.

[0145] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b is N. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, halogen or C1-C6 alkyl. In other embodiments, R 6b In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, F or -CH3. In other embodiments, R 6b is H. In other embodiments, R 6b is F. In other embodiments, R 6b In other embodiments, R 6b is D. In other embodiments, R 6b It is -C(CD3)3.

[0146] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2bis H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R 2b is C1-C6 alkoxy. In other embodiments, R 2b is -(C1-C6 alkylene)-OH. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH. In other embodiments, R 2b is H. In other embodiments, R 2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b is D. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0147] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4bis H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4b is -(C1-C6 alkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4bis -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b is -C(O)O(C1-C6 alkyl). In other embodiments, R 4b C6-C 10 In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, –CH3, –CH(CH3)2, –C(CH3)3, –C(CH3)2(CH2CH3), –CF3, –C(CH3)2(CHF2), –C(CH3)2(CF3) , –CH2C(CH3)2F, –C(=CH2)(CF3), –CH=C(CH3)2, –OCF3, –C(CH3)2(CH2OH), –C(CH3)(CF3)(CH2OH ), –C(CH3)2(C(O)OH), –C(CH3)(CF3)(C(O)OH), –C(O)OCH3, –Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl,

[0148] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 4bis H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -C(CH3)2(C(O)OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is H. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH2CH3). In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4b is 1-(methyl-d3)cyclopropyl. In other embodiments, R 4b is -C(CD3)(CH3)(CF3). In other embodiments, R 4b For -C( 13 CD3)(CH3)(CF3). In other embodiments, R 4b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5bis C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is H. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is -CH(CH3)2. In other embodiments, R 5b is -C(CH3)3. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b In other embodiments, R 5b is -C(CH3)2(CHF2). In other embodiments, R 5b is -CH2C(CH3)2F. In other embodiments, R 5b is -CH=C(CH3)2. In other embodiments, R 5b In other embodiments, R 5b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 5b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R5b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R 5b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for In other embodiments, R 5b for

[0149] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or C1-C6 alkyl. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or -CH3. In other embodiments, R 2b is H. In other embodiments, R 2b is -CH3.

[0150] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5b is N. In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or C1-C6 alkyl. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or -CH3. In other embodiments, R 5b is H. In other embodiments, R 5b is -CH3.

[0151] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, C1-C6 alkyl, -OH or -N(C1-C6 alkyl)2. In other embodiments, R 6b is a C1-C6 alkyl group. In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, -CH3, -OH, -N(CH3)2, -N(CH2CH2CH2)3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH2CH3), or -N(CH2CH(CH3)2)2. In other embodiments, R 6b is H. In other embodiments, R 6b In other embodiments, R 6b In other embodiments, R 6b is -N(CH3)2. In other embodiments, R 6b is -N(CH2CH2CH2)3. In other embodiments, R 6bis -N(CH3)(CH2CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH3)(CH2CH2CH2CH3). In other embodiments, R 6b It is -N(CH2CH(CH3)2)2.

[0152] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted by one to four R z In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is

[0153] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R z is C1-C6 alkyl or C1-C6 haloalkyl. z is a C1-C6 alkyl group. In other embodiments, R z In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R z In other embodiments, R z In other embodiments, R z It is -CF3.

[0154] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 7b is -CH3 or -CH(CH3)2. In other embodiments, R 7b In other embodiments, R 7b It is -CH(CH3)2.

[0155] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 9b It is -C(CH3)3.

[0156] In some embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 10b is H or Cl. In other embodiments, R 10b is H. In other embodiments, R 10b For Cl.

[0157] In some embodiments, the present invention relates to a compound of formula (IA):

[0158]

[0159] or a pharmaceutically acceptable salt thereof, wherein:

[0160] X 5a N or N + -O - ;

[0161] X 9a N or CR 9a ;

[0162] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0163] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0164] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0165] Y is

[0166] X 2b N or CR 2b ;

[0167] X 3b N or CR 3b ;

[0168] X 4b N or CR 4b ;

[0169] X 5b N or CR 5b ;

[0170] X 6b N or CR 6b ;

[0171] Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring;

[0172] R 2bis H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C( O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0173] R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0174] R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), -C 10 Aryl, C3-C 10Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace;

[0175] R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0176] R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)( C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0177] R 7b is a C1-C6 alkyl group;

[0178] R 9b is a C1-C6 alkyl group;

[0179] R 10b is H or halogen;

[0180] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and

[0181] R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH;

[0182] The conditions are:

[0183] (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than three of them are H; and

[0184] (ii) If Y is X 3b is N, and X 6b CR 6b , then R 2b 、R 4b 、R 5b and R 6b No more than three of them are H; and

[0185] (iii) If Y is X 3b CR 3b , and X 6b is N, then R 2b 、R 3b 、R 4b and R 5b No more than three of them are H; and

[0186] (iv) If X 9a N is N, Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6bNo more than two of are halo; and

[0187] (v) If X 9a N is N, Y is X 4b CR 4b , X 5b CR 5b , and X 6b CR 6b ,but:

[0188] R 4b 、R 5b and R 6b No more than two of them are H; or

[0189] Z is replaced by one or more R z replace.

[0190] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein:

[0191] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0192] Y is

[0193] R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0194] R 4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups.

[0195] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5a is N. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - .

[0196] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a And R 9ais H, halogen, C1-C6 alkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a And R 9a is H, halogen, C1-C6 alkyl or C1-C6 alkoxy. 9a In other embodiments, R 9a is a C1-C6 alkyl group. In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R 9a In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3, -OCH2CH3 or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 9a CR 9a And R 9a is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a It is -C(O)OCH3.

[0197] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 6ais H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is independently Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a is C1-C4 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)O(C1-C6 alkyl). In other embodiments, R 6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6ais -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is independently Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 6a For H, –CN, –OCH3, –NH(CH3), –N(CH3)2, –NHC(O)NH2, –NHC(O)NHCH3, –OH, –OCH2CH2OCH3, –OCH2CH2N(CH 3)2. –C(O)NH2, –C(O)NH(CH3), –C(O)N(CH3)2, –C(O)OH, –C(O)OCH3, –C(NH)NH2, –C(S)NH2, –SO2NH2, In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6a is -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)N(CH3)2. In other embodiments, R 6a In other embodiments, R 6aIn other embodiments, R 6a is -C(S)NH2. In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0198] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Y is

[0199] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3b is N. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, C1-C6 alkyl or C1-C6 haloalkyl. 3b is a C1-C6 alkyl group. In other embodiments, R 3b is a C1-C6 haloalkyl group. In other embodiments, R 3b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 3b is H, F, -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R3b is H, -CH3 or -CF3. In other embodiments, R 3b is H. In other embodiments, R 3b In other embodiments, R 3b In other embodiments, R 3b is D. In other embodiments, R 3b In other embodiments, R 3b For F.

[0200] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b is N. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, halogen or C1-C6 alkyl. In other embodiments, R 6b In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, F or -CH3. In other embodiments, R 6b is H. In other embodiments, R 6b is F. In other embodiments, R 6b In other embodiments, R 6b is D. In other embodiments, R 6b It is -C(CD3)3.

[0201] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R2b is C1-C6 alkoxy. In other embodiments, R 2b is -(C1-C6 alkylene)-OH. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH. In other embodiments, R 2b is H. In other embodiments, R 2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b is D. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0202] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C6 10The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4b is -(C1-C6 alkylene)-OH. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b is -C(O)O(C1-C6 alkyl). In other embodiments, R 4b C6-C 10 In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each Rb ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, –CH3, –CH(CH3)2, –C(CH3)3, –C(CH3)2(CH2CH3), –CF3, –C(CH3)2(CHF2), –C(CH3)2(CF3) , –CH2C(CH3)2F, –CH=C(CH3)2, –C(=CH2)(CF3), –OCF3, –C(CH3)2(CH2OH), –C(CH3)(CF3)(CH2OH ), –C(CH3)2(C(O)OH), –C(CH3)(CF3)(C(O)OH), –C(O)OCH3, –Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl, In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is H. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH2CH3). In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4bIn other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CHF2). In other embodiments, R 4b is -CH2C(CH3)2F. In other embodiments, R 4b is -CH=C(CH3)2. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R 4b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for

[0203] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5b is C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is H. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is -CH(CH3)2. In other embodiments, R 5b is -C(CH3)3. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b It is -C(CD3)3.

[0204] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or C1-C6 alkyl. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or -CH3. In other embodiments, R 2b is H. In other embodiments, R 2b is -CH3.

[0205] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5b is N. In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or C1-C6 alkyl. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or -CH3. In other embodiments, R 5b is H. In other embodiments, R 5b is -CH3.

[0206] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, C1-C6 alkyl or -N(C1-C6 alkyl)(C2-C6 alkyl). 6b is a C1-C6 alkyl group. In other embodiments, R6b In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, -CH3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH3), -N(CH2CH2CH3)2, or -N(CH2CH(CH3)2)2. In other embodiments, R 6b is H. In other embodiments, R 6b In other embodiments, R 6b is -N(CH3)(CH2CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH3)(CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH2CH3)2. In other embodiments, R 6b It is -N(CH2CH(CH3)2)2.

[0207] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted by one to four R z In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is

[0208] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R z In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R z is -CH3.

[0209] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 7bis -CH3 or -CH(CH3)2. In other embodiments, R 7b In other embodiments, R 7b It is -CH(CH3)2.

[0210] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 9b It is -C(CH3)3.

[0211] In some embodiments, the present invention relates to a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 10b is H or Cl. In other embodiments, R 10b is H. In other embodiments, R 10b For Cl.

[0212] In some embodiments, the present invention relates to a compound of formula (IB):

[0213]

[0214] or a pharmaceutically acceptable salt thereof, wherein:

[0215] X 5a N or N + -O - ;

[0216] R 3a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0217] R 4ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0218] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0219] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0220] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0221] Y is

[0222] X 2b N or CR 2b ;

[0223] X 3b N or CR 3b ;

[0224] X 4b N or CR 4b ;

[0225] X 5b N or CR 5b ;

[0226] X 6b N or CR 6b ;

[0227] Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring;

[0228] R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0229] R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0230] R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), -C 10 Aryl, C3-C 10Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace;

[0231] R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0232] R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)( C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0233] R 7b is a C1-C6 alkyl group;

[0234] R 9b is a C1-C6 alkyl group;

[0235] R 10b is H or halogen;

[0236] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and

[0237] R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH;

[0238] The conditions are:

[0239] (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than three of them are H.

[0240] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein:

[0241] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0242] Y is

[0243] R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl) C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0244] R 4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups.

[0245] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5a is N. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - .

[0246] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 3a In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 3a In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R3a is H. In other embodiments, R 3a is a C1-C6 alkyl group. In other embodiments, R 3a is -CH3.

[0247] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4a For H.

[0248] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is C1-C4 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)O(C1-C6 alkyl). In other embodiments, R 6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 6a For H, -CN, -OCH3, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OCH2CH2N(CH 3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2, In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6aIn other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6a is -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)N(CH3)2. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -C(S)NH2. In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0249] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -C(O)OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkyl or C1-C6 alkoxy. 9a In other embodiments, R 9a is a C1-C6 alkyl group. In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R 9a In other embodiments, R 9a In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3, -OCH2CH3, -C(O)OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9aIn other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a It is -C(O)OCH3.

[0250] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Y is

[0251] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3b is N. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, C1-C6 alkyl or C1-C6 haloalkyl. 3b is a C1-C6 alkyl group. In other embodiments, R 3b is a C1-C6 haloalkyl group. In other embodiments, R 3b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 3b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 3b CR3b And R 3b R 3b is H, -CH3 or -CF3. In other embodiments, R 3b is H. In other embodiments, R 3b In other embodiments, R 3b In other embodiments, R 3b is D. In other embodiments, R 3b In other embodiments, R 3b For F.

[0252] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b is N. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, halogen or C1-C6 alkyl. In other embodiments, R 6b In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, F or -CH3. In other embodiments, R 6b is H. In other embodiments, R 6b is F. In other embodiments, R 6b In other embodiments, R 6b is D. In other embodiments, R 6b It is -C(CD3)3.

[0253] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups. In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0254] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b is H. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R 2b is C1-C6 alkoxy. In other embodiments, R 2b is -(C1-C6 alkylene)-OH. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH. In other embodiments, R 2b is H. In other embodiments, R2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0255] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-(C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4bis -(C1-C6 alkylene)-OH. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b is -C(O)O(C1-C6 alkyl). In other embodiments, R 4b C6-C 10 In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4bis H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CHF2), -C(CH3)2(CF3) , -CH2C(CH3)2F, -CH=C(CH3)2, -C(=CH2)(CF3), -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH ), -C(CH3)2(C(O)OH), -C(CH3)(CF3)(C(O)OH), -C(O)OCH3, -Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl, In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is H. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH2CH3). In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4bis -C(CH3)2(CHF2). In other embodiments, R 4b is -CH2C(CH3)2F. In other embodiments, R 4b is -CH=C(CH3)2. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R 4b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for

[0256] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5b is C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is H. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is -CH(CH3)2. In other embodiments, R 5b is -C(CH3)3. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b It is -C(CD3)3.

[0257] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2b CR2b And R 2b is H or C1-C6 alkyl. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or -CH3. In other embodiments, R 2b is H. In other embodiments, R 2b is -CH3.

[0258] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5b is N. In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or C1-C6 alkyl. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or -CH3. In other embodiments, R 5b is H. In other embodiments, R 5b is -CH3.

[0259] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, C1-C6 alkyl or -N(C1-C6 alkyl)(C2-C6 alkyl). 6b is a C1-C6 alkyl group. In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b R6b is H, -CH3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH3), -N(CH2CH2CH3)2, or -N(CH2CH(CH3)2)2. In other embodiments, R 6b is H. In other embodiments, R 6b In other embodiments, R 6b is -N(CH3)(CH2CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH3)(CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH2CH3)2. In other embodiments, R 6b It is -N(CH2CH(CH3)2)2.

[0260] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted by one to four R z In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is

[0261] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R z In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R z is -CH3.

[0262] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 7b is -CH3 or -CH(CH3)2. In other embodiments, R 7b In other embodiments, R 7b It is -CH(CH3)2.

[0263] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 9b It is -C(CH3)3.

[0264] In some embodiments, the present invention relates to a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 10b is H or Cl. In other embodiments, R 10b is H. In other embodiments, R 10b For Cl.

[0265] In some embodiments, the present invention relates to a compound of formula (IC):

[0266]

[0267] or a pharmaceutically acceptable salt thereof, wherein:

[0268] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0269] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0270] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0271] Y is

[0272] X 2b N or CR 2b ;

[0273] X 3b N or CR 3b ;

[0274] X 4b N or CR 4b ;

[0275] X 5b N or CR 5b ;

[0276] X 6b N or CR 6b ;

[0277] Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring;

[0278] R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0279] R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0280] R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), -C 10 Aryl, C3-C 10Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace;

[0281] R 5b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups;

[0282] R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O (C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0283] R 7b is a C1-C6 alkyl group;

[0284] R 9b is a C1-C6 alkyl group;

[0285] R 10b is H or halogen;

[0286] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and

[0287] R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH;

[0288] The conditions are:

[0289] (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than three of them are H.

[0290] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein:

[0291] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0292] Y is

[0293] R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl) C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0294] R 4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups.

[0295] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 Ra 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is C1-C4 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)O(C1-C6 alkyl). In other embodiments, R 6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 6aFor H, -CN, -OCH3, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OCH2CH2N(CH 3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2, In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6a is -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)N(CH3)2. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -C(S)NH2. In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0296] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 9ais H, halogen, C1-C6 alkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkyl or C1-C6 alkoxy. 9a In other embodiments, R 9a is a C1-C6 alkyl group. In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R 9a is -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3, -OCH2CH3 or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a It is -C(O)OCH3.

[0297] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein Y is

[0298] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3bIs N. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b and R 3b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, C1-C6 alkyl or C1-C6 haloalkyl. 3b is a C1-C6 alkyl group. In other embodiments, R 3b is a C1-C6 haloalkyl group. In other embodiments, R 3b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 3b Is H, F, -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, -CH3 or -CF3. In other embodiments, R 3b is H. In other embodiments, R 3b In other embodiments, R 3b In other embodiments, R 3b is D. In other embodiments, R 3b In other embodiments, R 3b For F.

[0299] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b Is N. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, halogen or C1-C6 alkyl. In other embodiments, R 6b In other embodiments, R 6bIn some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, F or -CH3. In other embodiments, R 6b is H. In other embodiments, R 6b is F. In other embodiments, R 6b In other embodiments, R 6b is D. In other embodiments, R 6b It is -C(CD3)3.

[0300] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups. In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0301] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 2b is halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 2b is halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R 2b is C1-C6 alkoxy. In other embodiments, R 2bis -(C1-C6 alkylene)-OH. In other embodiments, R 2b is -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 2b is F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 2b is F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH. In other embodiments, R 2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0302] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4b is -(C1-C6 alkylene)-OH. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b is -C(O)(O)(C1-C6 alkyl). In other embodiments, R 4b C6-C 10 In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CHF2), -C(CH3)2(CF3) , -CH2C(CH3)2F, -CH=C(CH3)2, -C(=CH2)(CF3), -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH ), -C(CH3)2(C(O)OH), -C(CH3)(CF3)(C(O)OH), -C(O)OCH3, -Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl, In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is H. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH2CH3). In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4bis -C(CH3)2(CHF2). In other embodiments, R 4b is -CH2C(CH3)2F. In other embodiments, R 4b is -CH=C(CH3)2. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R 4b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for

[0303] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5b is C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is H. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is -CH(CH3)2. In other embodiments, R 5b is -C(CH3)3. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b It is -C(CD3)3.

[0304] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2b CR2b And R 2b is H or C1-C6 alkyl. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or -CH3. In other embodiments, R 2b is H. In other embodiments, R 2b is -CH3.

[0305] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5b Is N. In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or C1-C6 alkyl. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or -CH3. In other embodiments, R 5b is H. In other embodiments, R 5b is -CH3.

[0306] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, C1-C6 alkyl or -N(C1-C6 alkyl)(C2-C6 alkyl). 6b is a C1-C6 alkyl group. In other embodiments, R 6b is -N(C1-C6 alkyl)(C2-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6bis H, -CH3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH3), -N(CH2CH2CH3)2, or -N(CH2CH(CH3)2)2. In other embodiments, R 6b is H. In other embodiments, R 6b In other embodiments, R 6b is -N(CH3)(CH2CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH3)(CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH2CH3)2. In other embodiments, R 6b It is -N(CH2CH(CH3)2)2.

[0307] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted by one to four R z In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is

[0308] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R z In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R z is -CH3.

[0309] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 7b is -CH3 or -CH(CH3)2. In other embodiments, R 7b In other embodiments, R 7b It is -CH(CH3)2.

[0310] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 9b It is -C(CH3)3.

[0311] In some embodiments, the present invention relates to a compound of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 10b is H or Cl. In other embodiments, R 10b is H. In other embodiments, R 10b For Cl.

[0312] In some embodiments, the present invention relates to a compound of formula (ID):

[0313]

[0314] or a pharmaceutically acceptable salt thereof, wherein:

[0315] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0316] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0317] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0318] X 2b N or CR 2b ;

[0319] X 5b N or CR 5b ;

[0320] X 6b N or CR 6b ;

[0321] Z is a 5- to 7-membered aromatic or non-aromatic ring optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally surrounded by one or more R z replace;

[0322] R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0323] R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0324] R 6bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; and

[0325] R z It is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH.

[0326] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein:

[0327] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; and

[0328] R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

[0329] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 6a In other embodiments, R 6a In other embodiments, R 6a It is -C(O)NH2.

[0330] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 9a For H.

[0331] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or C1-C6 alkyl. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 2b CR 2b And R 2b is H or -CH3. In other embodiments, R 2b is H. In other embodiments, R 2b is -CH3.

[0332] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 2bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups. In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0333] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 5b is N. In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or C1-C6 alkyl. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 5b CR 5b And R 5b is H or -CH3. In other embodiments, R 5b is H. In other embodiments, R 5b is -CH3.

[0334] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, C1-C6 alkyl or -N(C1-C6 alkyl)(C2-C6 alkyl). 6bis a C1-C6 alkyl group. In other embodiments, R 6b is -N(C1-C6 alkyl)(C2-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, -CH3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH3), -N(CH2CH2CH3)2, or -N(CH2CH(CH3)2)2. In other embodiments, R 6b is H. In other embodiments, R 6b In other embodiments, R 6b is -N(CH3)(CH2CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH3)(CH2CH2CH3). In other embodiments, R 6b is -N(CH2CH2CH3)2. In other embodiments, R 6b It is -N(CH2CH(CH3)2)2.

[0335] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted by one to four R z In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is In other embodiments, Z is

[0336] In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R z In some embodiments, the present invention relates to a compound of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R z is -CH3.

[0337] In some embodiments, the present invention relates to a compound of formula (IE):

[0338]

[0339] or a pharmaceutically acceptable salt thereof, wherein:

[0340] X 5a N or N + -O - ;

[0341] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0342] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0343] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0344] X 3b N or CR 3b ;

[0345] X 6b N or CR 6b ;

[0346] R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0347] R 3bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0348] R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl), -C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace;

[0349] R 5bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1 -C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0350] R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl) C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0351] Each R b 'are independently C1-C6 alkyl or C1-C6 haloalkyl,

[0352] The condition is that if X 3b CR 3b And X 6b CR 6b , then R 2b 、R 3b 、R 4b 、R 5b and R 6b No more than three of them are H.

[0353] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein:

[0354] R 6ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0355] R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl) C6 haloalkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0356] R 4bis H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups.

[0357] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 5a is N. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - .

[0358] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 6ais H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is C1-C4 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R 6a is -C(O)O(C1-C6 alkyl). In other embodiments, R 6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 6a For H, -CN, -OCH3, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OCH2CH2N(CH 3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2, In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6a is -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)N(CH3)2. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -C(S)NH2. In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0359] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkyl or C1-C6 alkoxy. 9a In other embodiments, R 9a is a C1-C6 alkyl group. In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R9a In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein H, Cl, Br, -CH3, -OCH3, -OCH2CH3 or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a In other embodiments, R 9a It is -C(O)OCH3.

[0360] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 3b is N. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, C1-C6 alkyl or C1-C6 haloalkyl. 3b is a C1-C6 alkyl group. In other embodiments, R 3b is a C1-C6 haloalkyl group. In other embodiments, R 3b In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 3b Is H, F, -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 3b CR 3b And R 3b is H, -CH3 or -CF3. In other embodiments, R3b is H. In other embodiments, R 3b In other embodiments, R 3b In other embodiments, R 3b For F.

[0361] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 6b is N. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, halogen or C1-C6 alkyl. In other embodiments, R 6b In other embodiments, R 6b In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein X 6b CR 6b And R 6b is H, F or -CH3. In other embodiments, R 6b is H. In other embodiments, R 6b is F. In other embodiments, R 6b is -CH3.

[0362] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups. In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0363] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 2b is halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 2b is halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R 2b is C1-C6 alkoxy. In other embodiments, R 2b is -(C1-C6 alkylene)-OH. In other embodiments, R 2b is -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 2b is F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 2b is F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH. In other embodiments, R 2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0364] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 4bis H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -Si(C1-C6 alkyl)3, C6-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4b is -(C1-C6 alkylene)-OH. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b C6-C 10In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 4b It is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CH=C(CH3)2, -CF3, -C(CH3)2(CHF2), - C(CH3)2(CF3), -CH2C(CH3)2F, -C(=CH2)(CF3), -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH ), -C(CH3)2(C(O)OH), -C(CH3)(CF3)(C(O)OH), -C(O)OCH3, -Si(CH3)3, phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl, In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is H. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4bis -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH2CH3). In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4b is -CH=C(CH3)2. In other embodiments, R 4b is -C(CH3)2(CHF2). In other embodiments, R 4b is -CH2C(CH3)2F. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R 4b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for

[0365] In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5b is C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IE) or a pharmaceutically acceptable salt thereof, wherein R 5b is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is H. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R5b is -CH(CH3)2. In other embodiments, R 5b is -C(CH3)3. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b It is -C(CD3)3.

[0366] In some embodiments, the present invention relates to a compound of formula (IF):

[0367]

[0368] or a pharmaceutically acceptable salt thereof, wherein:

[0369] X 5a N, N + -O - or N + -CH3;

[0370] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0371] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0372] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0373] X 3b N or CH;

[0374] R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), - C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0375] R 4bis halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or a 4- to 10-membered heterocyclyl including 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclyl is optionally substituted with 1 to 2 R b 'replace;

[0376] R 5b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0377] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl.

[0378] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein:

[0379] R 6ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0380] R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0381] R 4bis halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

[0382] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein X 5a is N. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - .

[0383] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, C1-C6 alkoxy, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(NH)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 6a H, -CN, -OH, -C(O)NH 2、 -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH. In other embodiments, R 6a is -C(O)NH(C1-C6 alkyl). In other embodiments, R 6a is -C(O)N(C1-C6 alkyl)2. In other embodiments, R6a is -N(C1-C6 alkyl)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NH(C1-C6 alkyl). In other embodiments, R 6a is C1-C6 alkoxy. In other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a is a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'Replace; and each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 6a For H, -CN, -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH3, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(NH)NH2, -SO2NH2, In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, -OH, -C(O)NH2, -C(O)NH(CH3), -C(O)NH(CH3)2 or -C(O)OH. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -C(O)NH2. In other embodiments, R 6a is -C(O)NH(CH3). In other embodiments, R 6a is -C(O)NH(CH3)2. In other embodiments, R 6a In other embodiments, R 6a is -N(CH3)2. In other embodiments, R 6a is -NHC(O)NH2. In other embodiments, R 6a is -NHC(O)NHCH3. In other embodiments, R 6aIn other embodiments, R 6a is -C(NH)NH2. In other embodiments, R 6a In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for In other embodiments, R 6a for

[0384] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 9a is H or C1-C6 alkyl. In other embodiments, R 9a In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 9a is H or -CH3. In other embodiments, R 9a is H. In other embodiments, R 9a is -CH3.

[0385] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein X 3b is N. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein X 3b For CH.

[0386] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups. In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0387] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 2b is C1-C6 alkyl, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 2b is a C1-C6 alkyl group. In other embodiments, R2b is -(C1-C6 alkylene)-OH. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 2b is -CH3, -CH2OH or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 2b In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b It is -C(O)OCH3.

[0388] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 4b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, C6-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 4b is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl or -(C1-C6 alkylene)-OH. 4b In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is a C1-C6 haloalkenyl group. In other embodiments, R 4bis -(C1-C6 alkylene)-OH. In other embodiments, R 4b is C1-C6 alkenyl. In other embodiments, R 4b is C1-C6 haloalkoxy. In other embodiments, R 4b is -(C1-C6 haloalkylene)-OH. In other embodiments, R 4b is -(C1-C6 alkylene)-C(O)OH. In other embodiments, R 4b is -(C1-C6 haloalkylene)-C(O)OH. In other embodiments, R 4b C6-C 10 In other embodiments, R 4b C3-C 10 In other embodiments, R 4b is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen. 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'Replace; and each R b ' is independently -CH3 or -CF3. In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 4b Cl, -CH3, -CH(CH3)2, -C(CH3)3, -CH=C(CH3)2, -CF3, -C(CH3)2(CHF2), -C(CH3)2(CF3), -CH2C(CH3)2F, -C(=CH2)(CF3), -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH), -C(CH3)2(C(O)OH), -C(CH3)(CF3)(C(O)OH), phenyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, cyclobutyl, 1-methylcyclobutyl, 3,3-difluoro-1-methylcyclobutyl, cyclopentyl, 1-methylcyclopentyl, 1-trifluoromethylcyclopentyl, 3,3-difluoro-1-methylcyclopentyl, 4,4-difluoro-1-methylcyclohexyl, In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R4b is Cl, -CH3, -CH(CH3)2, -C(CH3)3, -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3) or -C(CH3)2(CH2OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is -CH(CH3)2. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -C(=CH2)(CF3). In other embodiments, R 4b is -C(CH3)2(CH2OH). In other embodiments, R 4b is D. In other embodiments, R 4b In other embodiments, R 4b is -CH=C(CH3)2. In other embodiments, R 4b is -C(CH3)2(CHF2). In other embodiments, R 4b is -CH2C(CH3)2F. In other embodiments, R 4b In other embodiments, R 4b is -C(CH3)(CF3)(CH2OH). In other embodiments, R 4b is -C(CH3)2(C(O)OH). In other embodiments, R 4b is -C(CH3)(CF3)(C(O)OH). In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclobutyl. In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b In other embodiments, R 4b is 3,3-difluoro-1-methylcyclopentyl. In other embodiments, R4b is 4,4-difluoro-1-methylcyclohexyl. In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for In other embodiments, R 4b for

[0389] In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 5b is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. 5b In other embodiments, R 5b is a C1-C6 alkyl group. In other embodiments, R 5b is a C1-C6 haloalkyl group. In other embodiments, R 5b is C1-C6 alkoxy. In other embodiments, R 5b In some embodiments, the present invention relates to a compound of formula (IF) or a pharmaceutically acceptable salt thereof, wherein R 5b is F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -CF3, -OCH3 or cyclopropyl. In other embodiments, R 5b is F. In other embodiments, R 5b In other embodiments, R5b In other embodiments, R 5b In other embodiments, R 5b is -CH(CH3)2. In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b In other embodiments, R 5b is D. In other embodiments, R 5b It is -C(CD3)3.

[0390] In some embodiments, the present invention relates to a compound of formula (IG):

[0391]

[0392] or a pharmaceutically acceptable salt thereof, wherein:

[0393] X 5a N or N + -O - ;

[0394] R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyloxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace;

[0395] R 9ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0396] Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2;

[0397] X 3b N or CH;

[0398] R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), - C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl), C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups;

[0399] R 4bis halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups and the heterocyclic group is optionally substituted with 1 to 2 R b 'replace; and

[0400] Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl.

[0401] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein:

[0402] R 6ais H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2;

[0403] R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halo groups; and

[0404] R 4bis halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

[0405] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein X 5a Is N. In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein X 5a N + -O - .

[0406] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2. In other embodiments, R 6a is C1-C4 alkoxy. In other embodiments, R 6a is -NH(C1-C6 alkyl). In other embodiments, R 6a is -O(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 6a is -O(C1-C6 alkylene)-N(C1-C6 alkyl)2. In other embodiments, R 6a In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 6ais H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, C(O)NH2, -C(O)OH, -C(O)OCH3 or -C(S)NH2. In other embodiments, R 6a is H. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -NH(CH3). In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a is -OCH2CH2N(CH3)2. In other embodiments, R 6a is C(O)NH2. In other embodiments, R 6a In other embodiments, R 6a In other embodiments, R 6a It is -C(S)NH2.

[0407] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl). In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, halogen or C1-C6 alkoxy. In other embodiments, R 9a In other embodiments, R 9a is C1-C6 alkoxy. In other embodiments, R 9a In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -OCH3, -OCH2CH3 or -C(O)OCH3. In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 9a is H, Cl, Br, -OCH3 or -OCH2CH3. In other embodiments, R 9a is H. In other embodiments, R 9a In other embodiments, R 9a is Br. In other embodiments, R 9a In other embodiments, R 9aIn other embodiments, R 9a It is -C(O)OCH3.

[0408] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein X 3b Is N. In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein X 3b For CH.

[0409] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

[0410] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 2b is halo, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH. In other embodiments, R 2b In other embodiments, R 2b is a C1-C6 alkyl group. In other embodiments, R 2b is C1-C6 alkoxy. In other embodiments, R 2b In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 2b is F, Cl, -CH3, -CH2CH3, -OCH3 or -OCH2CH2CH2OH. In other embodiments, R 2b is F. In other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2bIn other embodiments, R 2b In other embodiments, R 2b In other embodiments, R 2b is D. In other embodiments, R 2b It is -C(CD3)3.

[0411] In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 4b is C1-C6 alkyl, C1-C6 haloalkyl, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4b is a C1-C6 alkyl group. In other embodiments, R 4b is a C1-C6 haloalkyl group. In other embodiments, R 4b is -Si(C1-C6 alkyl)3. In other embodiments, R 4b is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In some embodiments, the present invention relates to a compound of formula (IG) or a pharmaceutically acceptable salt thereof, wherein R 4b is -C(CH3)3, -C(CH3)2(CH2)(CH3), -C(CH3)2(CF3), -Si(CH3)3 or 1-trifluoromethylcyclopropyl. In other embodiments, R 4b is -C(CH3)3. In other embodiments, R 4b is -C(CH3)2(CH-2)(CH3). In other embodiments, R 4b is -C(CH3)2(CF3). In other embodiments, R 4b is -Si(CH3)3. In other embodiments, R 4b In other embodiments, R 4b is D. In other embodiments, R 4b It is -C(CD3)3.

[0412] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein:

[0413] R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2; and

[0414] Y is

[0415] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R3c is H, halogen or C1-C6 alkyl. In other embodiments, R 3c In other embodiments, R 3c In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 3c is H, F or -CH3. In other embodiments, R 3c is H. In other embodiments, R 3c is F. In other embodiments, R 3c is -CH3.

[0416] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, halogen, -CN or C1-C6 alkoxy. In other embodiments, R 4c In other embodiments, R 4c In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, F, -CN or -OCH3. In other embodiments, R 4c is H. In other embodiments, R 4c is F. In other embodiments, R 4c In other embodiments, R 4c It is -OCH3.

[0417] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl). 5c In other embodiments, R 5c is a C1-C6 alkyl group. In other embodiments, R 5c is a C1-C6 haloalkyl group. In other embodiments, R 5c is C1-C6 alkoxy. In other embodiments, R 5c In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, F, -CN, -CH3, -CF3, -OCH3 or -C(O)OCH3. In other embodiments, R 5c is H. In other embodiments, R 5c is F. In other embodiments, R 5cIn other embodiments, R 5c In other embodiments, R 5c In other embodiments, R 5c In other embodiments, R 5c It is -C(O)OCH3.

[0418] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 6c H, F, Cl, -OH, -CN, -OCH3, C(O)NH2 or In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2. In other embodiments, R 6c In other embodiments, R 6c In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, F, Cl, -OH, -CN, -OCH3 or C(O)NH2. In other embodiments, R 6c is H. In other embodiments, R 6c is F. In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c is C(O)NH2. In other embodiments, R 6c for

[0419] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl) or -C(O)O(C1-C6 alkyl). In other embodiments, R 9c is a C1-C6 alkyl group. In other embodiments, R 9c is -(C1-C6 alkylene)-OH. In other embodiments, R 9c is -(C1-C6 alkylene)-O(C1-C6 alkyl). In other embodiments, R 9cIn some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, -CH3, -CH2OH, -CH2OCH3 or -C(O)OCH2CH3. In other embodiments, R 9c is H. In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c It is -C(O)OCH2CH3.

[0420] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein Y is In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein Y is

[0421] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d is N. In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d And R 3d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy. 3d In other embodiments, R 3d is a C1-C6 alkyl group. In other embodiments, R 3d is a C1-C6 haloalkyl group. In other embodiments, R 3d is C1-C6 alkoxy. In other embodiments, R 3d In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d And R 3d is H, F, Cl, -CH3, -CH2CH3, -CF3, -OCH3, -OCH2CH3 or -OCF3. In other embodiments, R 3d is H. In other embodiments, R 3d is F. In other embodiments, R3d In other embodiments, R 3d In other embodiments, R 3d In other embodiments, R 3d In other embodiments, R 3d In other embodiments, R 3d In other embodiments, R 3d is -OCF3.

[0422] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d ; and R 2d and R 3d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 2d and R 3d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 2d and R 3d Together with the carbon atom to which they are attached, they form the formula Ring.

[0423] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d ; and R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula Ring.

[0424] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH. 2d In other embodiments, R 2d is a C1-C6 alkyl group. In other embodiments, R 2d is C1-C6 alkoxy. In other embodiments, R 2d is C1-C6 haloalkoxy. In other embodiments, R 2d In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 2d is H, F, Cl, -OH, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCF3 or -CH2OH. In other embodiments, R 2d is H. In other embodiments, R 2d is F. In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d is -CH(CH3)2. In other embodiments, R 2d is -C(CH3)3. In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d is -OCH(CH3)2. In other embodiments, R 2d In other embodiments, R 2d It is -CH2OH.

[0425] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4d R is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN. In other embodiments, R 4d In other embodiments, R 4d is a C1-C6 alkyl group. In other embodiments, R 4d is a C1-C6 haloalkyl group. In other embodiments, R 4d is a C1-C6 haloalkenyl group. In other embodiments, R 4d is C1-C6 alkoxy. In other embodiments, R 4d is C1-C6 haloalkoxy. In other embodiments, R 4d is -(C1-C6 alkylene)-OH. In other embodiments, R 4d is -(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 4d is -Si(C1-C6 alkyl)3. In other embodiments, R 4d is -C(O)O(C1-C6 alkyl). In other embodiments, R 4d is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally substituted with one or more halogens or -CN. In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 4dR is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3, -CF3, -CH(CH3)(CF3), -C(CH3)2(CF3), -C(=CH2)(CF3), -OCH3, -OCH(CH3)2, -OC(CH3)3, -OCF3, -C(CH3)2OH, -C(CH3)2(OCH3), -Si(CH3)3, -C(O)OCH2CH3, cyclopropyl, 1-cyanocyclopropyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, 1-methylcyclobutyl or 3,3-difluorocyclobutyl. In other embodiments, R 4d is H. In other embodiments, R 4d is F. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)2. In other embodiments, R 4d is -C(CH3)3. In other embodiments, R 4d is -CH2C(CH3)3. In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)(CF3). In other embodiments, R 4d is -C(CH3)2(CF3). In other embodiments, R 4d is -C(=CH2)(CF3). In other embodiments, R 4d In other embodiments, R 4d is -OCH(CH3)2. In other embodiments, R 4d is -OC(CH3)3. In other embodiments, R 4d In other embodiments, R 4d is -C(CH3)2OH. In other embodiments, R 4d is -C(CH3)2(OCH3). In other embodiments, R 4d is -Si(CH3)3. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R4d In other embodiments, R 4d It is 3,3-difluorocyclobutyl.

[0426] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 5d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or -C(O)(C1-C6 alkyl). 5d In other embodiments, R 5d is a C1-C6 alkyl group. In other embodiments, R 5d is a C1-C6 haloalkyl group. In other embodiments, R 5d is C1-C6 alkoxy. In other embodiments, R 5d In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 5d is H, F, Cl, Br, -CH3, -C(CH3)3, -CF3, -OCH3 or -C(O)CH3. In other embodiments, R 5d is H. In other embodiments, R 5d is F. In other embodiments, R 5d In other embodiments, R 5d is Br. In other embodiments, R 5d In other embodiments, R 5d is -C(CH3)3. In other embodiments, R 5d In other embodiments, R 5d In other embodiments, R 5d It is -C(O)CH3.

[0427] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 6d is H, halogen or C1-C6 alkyl. In other embodiments, R 6d In other embodiments, R 6d In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 6d is H, Cl or -CH3. In other embodiments, R 6d is H. In other embodiments, R 6d In other embodiments, R 6d is -CH3.

[0428] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 7d is -CH3.

[0429] In some embodiments, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 9d It is -C(CH3)3.

[0430] In some embodiments, the present invention relates to a compound of formula (II-A):

[0431]

[0432] or a pharmaceutically acceptable salt thereof, wherein:

[0433] R 3c is H, halogen or C1-C6 alkyl;

[0434] R 4c is H, halogen, -CN or C1-C6 alkoxy;

[0435] R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy;

[0436] R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen;

[0437] R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl);

[0438] X 3d N or CR 3d ;

[0439] R 2d 、R 3d and R 4d The definition is as follows:

[0440] (i)R 2d is H, halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy;

[0441] R 3d is H or halo; and

[0442] R 4dis H, chlorine, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or

[0443] (ii)R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or -(C1-C6 alkylene)-OH; and

[0444] R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula:

[0445]

[0446] R 5d is H, halo, C1-C6 alkyl or C1-C6 haloalkyl; and

[0447] R 6d is H, halogen or C1-C6 alkyl,

[0448] The conditions are:

[0449] (i) If X 3d is N, then R 2d 、R 4d 、R 5d and R 6d No more than two of them are H; and

[0450] (ii) If R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula:

[0451]

[0452] Then R 2d 、R 5d and R 6d No more than two of them are H; and

[0453] (iii) If R 4d is H, then R 2d is a C1-C6 alkyl group and R5d is a C1-C6 alkyl group or a C1-C6 haloalkyl group; and

[0454] (iv) If R 4d is chlorine, then R 2d is -OH or C1-C6 alkyl; and

[0455] (v) If R 4d is -CH3, then R 2d is -OH, C1-C6 alkyl or C1-C2 alkoxy; and

[0456] (vi) If R 4d is -C(CH3)3, then R 2d is H, chlorine, -OH, C1-C6 alkyl or C1-C6 alkoxy; and

[0457] (vii) If R 4d is -CF3, then R 2d is a C1-C6 alkyl group or a C1-C6 alkoxy group; and

[0458] (viii) If R 4d is -OCH3, then R 2d is halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy; and R 5d is halo, C1-C6 alkyl or C1-C6 haloalkyl; and

[0459] (ix) If R 4d is -OC(CH3)3, then R 2d 、R 3d 、R 5d and R 6d No more than three of them are H;

[0460] (x) If R 4d For -OCF3, then R 2d is halo, -OH, C1-C6 alkyl or C1-C6 alkoxy; and

[0461] (xi) If R 4d is cyclopropyl, then R 2d is H, chlorine, -OH, C1-C6 alkyl or C1-C6 alkoxy; and R 6d is H or C1-C6 alkyl; and

[0462] (xii) If R 2d is -OCH3 and R 4d is -CH3, then R 5d is a halogen group, a C1-C6 alkyl group or a C1-C6 haloalkyl group.

[0463] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

[0464] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 3c is H, halogen or C1-C6 alkyl. In other embodiments, R 3c In other embodiments, R 3c In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 3c is H, F or -CH3. In other embodiments, R 3c is H. In other embodiments, R 3c is F. In other embodiments, R 3c is -CH3.

[0465] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, halogen, -CN or C1-C6 alkoxy. In other embodiments, R 4c In other embodiments, R 4c In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, F, -CN or -OCH3. In other embodiments, R 4c is H. In other embodiments, R 4c is F. In other embodiments, R 4c In other embodiments, R 4c It is -OCH3.

[0466] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy. 5c In other embodiments, R 5c is a C1-C6 alkyl group. In other embodiments, R 5c In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, F, -CN, -CH3 or -OCH3. In other embodiments, R 5c is H. In other embodiments, R5c is F. In other embodiments, R 5c In other embodiments, R 5c In other embodiments, R 5c It is -OCH3.

[0467] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6c H, F, Cl, -OH, -CN, -OCH3, -C(O)NH2 or In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2. In other embodiments, R 6c In other embodiments, R 6c In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, F, Cl, -OH, -CN, -OCH3 or -C(O)NH2. In other embodiments, R 6c is H. In other embodiments, R 6c is F. In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c is -C(O)NH2. In other embodiments, R 6c for

[0468] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl) or -C(O)O(C1-C6 alkyl). In other embodiments, R 9c is a C1-C6 alkyl group. In other embodiments, R 9c is -(C1-C6 alkylene)-OH. In other embodiments, R 9c is -(C1-C6 alkylene)-O(C1-C6 alkyl). In other embodiments, R 9cIn some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, -CH3, -CH2OH, -CH2OCH3 or -C(O)OCH2CH3. In other embodiments, R 9c is H. In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c It is -C(O)OCH2CH3.

[0469] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein X 3d is N. In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d And R 3d is H or halogen. In other embodiments, R 3d In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d And R 3d is H or Cl. In other embodiments, R 3d is H. In other embodiments, R 3d For Cl.

[0470] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein X 3d CR 3d ; and R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R4d Together with the carbon atom to which they are attached, they form the formula In other embodiments, R 3d and R 4d Together with the carbon atom to which they are attached, they form the formula Ring.

[0471] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 2d is H, halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy. 2d In other embodiments, R 2d is a C1-C6 alkyl group. In other embodiments, R 2d In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 2d In other embodiments, R 2d is H. In other embodiments, R 2d is F. In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d is -CH(CH3)2. In other embodiments, R 2d In other embodiments, R 2d It is -OCH2CH3.

[0472] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 4d R is H, chlorine, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogens or -CN. In other embodiments, R 4dis a C1-C6 alkyl group. In other embodiments, R 4d is a C1-C6 haloalkyl group. In other embodiments, R 4d is a C1-C6 haloalkenyl group. In other embodiments, R 4d is C1-C6 alkoxy. In other embodiments, R 4d is C1-C6 haloalkoxy. In other embodiments, R 4d is -(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 4d is -Si(C1-C6 alkyl)3. In other embodiments, R 4d is -C(O)O(C1-C6 alkyl). In other embodiments, R 4d is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d or C3-C6 cycloalkyl, wherein the cycloalkyl is optionally substituted with one or more halogens or -CN. In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 4d is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3, -CF3, -CH(CH3)(CF3), -C(CH3)2(CF3), -C(=CH2)(CF3), -OCH3, -OCF3, -C(CH3)2(CH2OCH3), -Si(CH3)3, -C(O)OCH2CH3, cyclopropyl, 1-cyanocyclopropyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, 1-methylcyclobutyl or 3,3-difluorocyclobutyl. In other embodiments, R 4d is H. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)2. In other embodiments, R 4d is -C(CH3)3. In other embodiments, R 4d is -CH2C(CH3)3. In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)(CF3). In other embodiments, R 4d is -C(CH3)2(CF3). In other embodiments, R 4d is -C(=CH2)(CF3). In other embodiments, R 4dIn other embodiments, R 4d In other embodiments, R 4d is -C(CH3)2(CH2OCH3). In other embodiments, R 4d is -Si(CH3)3. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d It is 3,3-difluorocyclobutyl.

[0473] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 5d is H, halo, C1-C6 alkyl or C1-C6 haloalkyl. 5d In other embodiments, R 5d is a C1-C6 alkyl group. In other embodiments, R 5d In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 5d is H, F, Cl, Br, -CH3, -C(CH3)3 or -CF3. In other embodiments, R 5d is H. In other embodiments, R 5d is F. In other embodiments, R 5d In other embodiments, R 5d is Br. In other embodiments, R 5d In other embodiments, R 5d is -C(CH3)3. In other embodiments, R 5d It is -CF3.

[0474] In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6d is H, halogen or C1-C6 alkyl. In other embodiments, R 6d In other embodiments, R 6d In some embodiments, the present invention relates to a compound of formula (II-A) or a pharmaceutically acceptable salt thereof, wherein R 6dis H, Cl or -CH3. In other embodiments, R 6d is H. In other embodiments, R 6d In other embodiments, R 6d is -CH3.

[0475] In some embodiments, the present invention relates to a compound of formula (II-B):

[0476]

[0477] or a pharmaceutically acceptable salt thereof, wherein:

[0478] R 3c is H, halogen or C1-C6 alkyl;

[0479] R 4c is H, halogen, -CN or C1-C6 alkoxy;

[0480] R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy;

[0481] R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen;

[0482] R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl);

[0483] X 3d N or CH;

[0484] R 2d is halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy;

[0485] R 4d is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and

[0486] R 5d is halogen, C1-C6 alkyl or C1-C6 haloalkyl,

[0487] The conditions are:

[0488] (i) If R 2d is chlorine, then X 3d is N; and

[0489] (ii) If R 4d is -CH3 and R 5d is -CH3, then R 2d It is -OH, C1-C6 alkyl or C1-C2 alkoxy.

[0490] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

[0491] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 3c is H or halogen. In other embodiments, R 3c In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 3c is H or F. In other embodiments, R 3c is H. In other embodiments, R 3c For F.

[0492] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, halogen, -CN or C1-C6 alkoxy. In other embodiments, R 4c In other embodiments, R 4c In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, F, -CN or -OCH3. In other embodiments, R 4c is H. In other embodiments, R 4c is F. In other embodiments, R 4c In other embodiments, R 4c It is -OCH3.

[0493] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 5cis H, halogen or C1-C6 alkoxy. In other embodiments, R 5c In other embodiments, R 5c In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, F or -OCH3. In other embodiments, R 5c is H. In other embodiments, R 5c is F. In other embodiments, R 5c It is -OCH3.

[0494] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 6c H, F, Cl, -OH, -CN, -OCH3, -C(O)NH2 or In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2. In other embodiments, R 6c In other embodiments, R 6c In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, F, Cl, -OH, -CN, -OCH3 or -C(O)NH2. In other embodiments, R 6c is H. In other embodiments, R 6c is F. In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c is -C(O)NH2. In other embodiments, R 6c for

[0495] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 9c For H.

[0496] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein X 3d is N. In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein X 3dFor CH.

[0497] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 2d is halogen, C1-C6 alkyl or C1-C6 alkoxy. 2d In other embodiments, R 2d is a C1-C6 alkyl group. In other embodiments, R 2d In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 2d is F, Cl, -CH3 or -OCH3. In other embodiments, R 2d is F. In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d It is -OCH3.

[0498] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 4d is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl or C1-C6 alkoxy. 4d In other embodiments, R 4d is a C1-C6 alkyl group. In other embodiments, R 4d is a C1-C6 haloalkyl group. In other embodiments, R 4d is a C1-C6 haloalkenyl group. In other embodiments, R 4d In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 4d is Cl, -CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH(CH3)(CF3), -C(CH3)2(CF3), -C(=CH2)(CF3) or -OCH3. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)2. In other embodiments, R 4d is -C(CH3)3. In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)(CF3). In other embodiments, R 4dis -C(CH3)2(CF3). In other embodiments, R 4d is -C(=CH2)(CF3). In other embodiments, R 4d It is -OCH3.

[0499] In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 5d is halogen or C1-C6 alkyl. In other embodiments, R 5d In other embodiments, R 5d In some embodiments, the present invention relates to a compound of formula (II-B) or a pharmaceutically acceptable salt thereof, wherein R 5d is F, Cl, Br or -CH3. In other embodiments, R 5d is F. In other embodiments, R 5d In other embodiments, R 5d is Br. In other embodiments, R 5d is -CH3.

[0500] In some embodiments, the present invention relates to a compound of formula (II-C):

[0501]

[0502] or a pharmaceutically acceptable salt thereof, wherein:

[0503] R 3c is H, halogen or C1-C6 alkyl;

[0504] R 4c is H, halogen, -CN or C1-C6 alkoxy;

[0505] R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy;

[0506] R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen;

[0507] R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl);

[0508] X 3d N or CH;

[0509] R 2dis -OH, C1-C6 alkyl or C1-C6 alkoxy; and

[0510] R 4d is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN;

[0511] The conditions are:

[0512] (i) If R 2d is -OH, then R 4d is halo, C1-C6 alkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and

[0513] (ii) If R 2d is -CH3, then R 4d is halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and

[0514] (iii) If R 2d is -OCH3, then R 4dIt is C2-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN.

[0515] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

[0516] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 3c is H, halogen or C1-C6 alkyl. In other embodiments, R 3c In other embodiments, R 3c In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 3c is H, F or -CH3. In other embodiments, R 3c is H. In other embodiments, R 3c is F. In other embodiments, R 3c is -CH3.

[0517] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, halogen, -CN or C1-C6 alkoxy. In other embodiments, R 4c In other embodiments, R 4c In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 4c is H, F, -CN or -OCH3. In other embodiments, R 4c is H. In other embodiments, R 4c is F. In other embodiments, R 4c In other embodiments, R 4c It is -OCH3.

[0518] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy. 5c In other embodiments, R 5c is a C1-C6 alkyl group. In other embodiments, R 5c In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 5c is H, F, -CN, -CH3 or -OCH3. In other embodiments, R 5c is H. In other embodiments, R 5c is F. In other embodiments, R 5c In other embodiments, R 5c In other embodiments, R 5c It is -OCH3.

[0519] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2. In other embodiments, R 6c In other embodiments, R 6c In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 6c is H, F, -OH, -CN, -OCH3 or -C(O)NH2. In other embodiments, R 6c is H. In other embodiments, R 6c is F. In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c In other embodiments, R 6c It is -C(O)NH2.

[0520] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl) or -C(O)O(C1-C6 alkyl). In other embodiments, R 9c is H. In other embodiments, R 9c is a C1-C6 alkyl group. In other embodiments, R9c is -(C1-C6 alkylene)-OH. In other embodiments, R 9c is -(C1-C6 alkylene)-O(C1-C6 alkyl). In other embodiments, R 9c In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 9c is H, -CH3, -CH2OH, -CH2OCH3 or -C(O)OCH2CH3. In other embodiments, R 9c is H. In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c In other embodiments, R 9c It is -C(O)OCH2CH3.

[0521] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein X 3d is N. In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein X 3d For CH.

[0522] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 2d is -OH, C1-C6 alkyl or C1-C6 alkoxy. 2d is a C1-C6 alkyl group. In other embodiments, R 2d In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d In other embodiments, R 2d is -CH(CH3)2. In other embodiments, R 2d In other embodiments, R 2d It is -OCH2CH3.

[0523] In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R4d is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or C3-C6 cycloalkyl, wherein the cycloalkyl in said C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN. In other embodiments, R 4d In other embodiments, R 4d is a C1-C6 alkyl group. In other embodiments, R 4d is a C1-C6 haloalkyl group. In other embodiments, R 4d is C1-C6 haloalkoxy. In other embodiments, R 4d is -(C1-C6 alkylene)-(C1-C6 alkoxy). In other embodiments, R 4d is -Si(C1-C6 alkyl)3. In other embodiments, R 4d is -C(O)O(C1-C6 alkyl). In other embodiments, R 4d is (C1-C6 alkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d is (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. In other embodiments, R 4d is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally substituted with one or more halogens or -CN. In some embodiments, the present invention relates to a compound of formula (II-C) or a pharmaceutically acceptable salt thereof, wherein R 4d is Cl, -CH3, -CH(CH3)2, -C(CH3)3, -CH2C(CH3)3, -CF3, -C(CH3)2(CF3), -OCF3, -CH(CH2)(OCH3), -Si(CH3)3, -C(O)OCH2CH3, cyclopropyl, 1-cyanocyclopropyl, 1-methylcyclopropyl, 1-trifluoromethylcyclopropyl, 1-methylcyclobutyl or 3,3-difluorocyclobutyl. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d is -CH(CH3)2. In other embodiments, R 4d is -C(CH3)3. In other embodiments, R 4d is -CH2C(CH3)3. In other embodiments, R 4dIn other embodiments, R 4d is -C(CH3)2(CF3). In other embodiments, R 4d In other embodiments, R 4d is -CH(CH2)(OCH3). In other embodiments, R 4d is -Si(CH3)3. In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d In other embodiments, R 4d It is 3,3-difluorocyclobutyl.

[0524] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 6k It is H, -OH or C1-C6 alkoxy.

[0525] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 3k is N. In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 3k For CH.

[0526] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 4k is N. In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 4k For CH.

[0527] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 5k is N. In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k And R 5kis H, C1-C6 alkoxy, -OH, -OCH2CH2N(CH3)2 or -N(CH3)(CH2CH2OCH3). In other embodiments, R 5k In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k And R 5k is H, -OH, -OCH3, -OCH2CH2N(CH3)2 or -N(CH3)(CH2CH2OCH3). In other embodiments, R 5k is H. In other embodiments, R 5k In other embodiments, R 5k In other embodiments, R 5k is -OCH2CH2N(CH3)2. In other embodiments, R 5k It is -N(CH3)(CH2CH2OCH3).

[0528] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 6k is N. In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 6k N + -O - In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k Is H, -OH, -OCH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k is H, -OH or C1-C6 alkoxy. In other embodiments, R 6k In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k is H, -OH or -OCH3. In other embodiments, R 6k is H. In other embodiments, R 6k In other embodiments, R 6k In other embodiments, R 6k It is -C(O)NH2.

[0529] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2L is -CH3.

[0530] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. 4L is a C1-C6 alkyl group. In other embodiments, R 4L is a C1-C6 haloalkyl group. In other embodiments, R 4L In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 4L is -C(CH3)3, -C(CH3)2(CF3) or 1-trifluoromethylcyclopropyl. In other embodiments, R 4L is -C(CH3)3. In other embodiments, R 4L is -C(CH3)2(CF3). In other embodiments, R 4L It is 1-trifluoromethylcyclopropyl.

[0531] In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 5L is H, halogen or C1-C6 alkyl. In other embodiments, R 5L In other embodiments, R 5L In some embodiments, the present invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 5L is H, F, Cl or -CH3. In other embodiments, R 5L is H. In other embodiments, R 5L is F. In other embodiments, R 5L In other embodiments, R 5L is -CH3.

[0532] In some embodiments, the present invention relates to a compound of formula (III-A):

[0533]

[0534] or a pharmaceutically acceptable salt thereof, wherein:

[0535] X 3k N or CH;

[0536] X 4k N or CH;

[0537] X 5k N or CR 5k ;

[0538] X 6k N, N + -O - or CR 6k ;

[0539] R 5k is H, C1-C6 alkoxy, -OH or -OCH2CH2N(CH3)2;

[0540] R 6k is H, -OH, C1-C6 alkoxy or -C(O)NH2;

[0541] R 2L is a C1-C6 alkyl group;

[0542] R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-; and

[0543] R 5L is H, halogen or C1-C6 alkyl,

[0544] The conditions are:

[0545] (i)X 3k 、X 4k 、X 5k and X 6k No more than two of them are N; and

[0546] (ii) If X 6k N + -O - , then X 3k and X 4k is CH, and X 5k CR 5k ;and

[0547] (iii) If X 5k is N, then X 4k is N.

[0548] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 6k It is H, -OH or C1-C6 alkoxy.

[0549] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X3k is N. In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 3k For CH.

[0550] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 4k is N. In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 4k For CH.

[0551] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 5k is N. In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k And R 5k is H, C1-C6 alkoxy, -OH or -OCH2CH2N(CH3)2. In other embodiments, R 5k In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 5k CR 5k And R 5k is H, -OCH3, -OH or -OCH2CH2N(CH3)2. In other embodiments, R 5k is H. In other embodiments, R 5k In other embodiments, R 5k In other embodiments, R 5k It is -OCH2CH2N(CH3)2.

[0552] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k is N. In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k N + -O - In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6kIn some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k Is H, -OH, -OCH3 or -C(O)NH2. In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein X 6k CR 6k And R 6k is H, -OH or -OCH3. In other embodiments, R 6k is H. In other embodiments, R 6k In other embodiments, R 6k In other embodiments, R 6k It is -C(O)NH2.

[0553] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 2L is -CH3.

[0554] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-. 4L is a C1-C6 alkyl group. In other embodiments, R 4L is a C1-C6 haloalkyl group. In other embodiments, R 4L In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 4L is -C(CH3)3, -C(CH3)2(CF3) or 1-trifluoromethylcyclopropyl. In other embodiments, R 4L is -C(CH3)3. In other embodiments, R 4L is -C(CH3)2(CF3). In other embodiments, R 4L It is 1-trifluoromethylcyclopropyl.

[0555] In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 5L is H, halogen or C1-C6 alkyl. In other embodiments, R 5L In other embodiments, R 5L In some embodiments, the present invention relates to a compound of formula (III-A) or a pharmaceutically acceptable salt thereof, wherein R 5L is H, F, Cl or -CH3. In other embodiments, R 5L is H. In other embodiments, R 5L is F. In other embodiments, R 5L In other embodiments, R 5L is -CH3.

[0556] In some embodiments, the present invention relates to a compound selected from Table A or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to a compound selected from Table A, ie, a compound in non-salt form.

[0557] Table A. Compound structures and names.

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595] In some embodiments, the present invention relates to a compound selected from Table B or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to a compound selected from Table B, ie, a compound in non-salt form.

[0596] Table B. Compound structures and names.

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617] In some embodiments, the present invention relates to compounds of the formula

[0618]

[0619] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0620] In some embodiments, the present invention relates to the compound 2-(4-tert-butyl-5-chloro-2-methyl-phenyl)-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0621] In some embodiments, the present invention relates to compounds of the formula

[0622]

[0623] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0624] In some embodiments, the present invention relates to the compound 2-[5-chloro-2-methyl-4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0625] In some embodiments, the present invention relates to compounds of the formula

[0626]

[0627] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0628] In some embodiments, the present invention relates to the compound 2-(6-tert-butyl-5-chloro-2-methyl-3-pyridyl)-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0629] In some embodiments, the present invention relates to compounds of the formula

[0630]

[0631] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0632] In some embodiments, the present invention relates to the compound 2-[4-tert-butyl-2-methyl-5-(trifluoromethyl)phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0633] In some embodiments, the present invention relates to compounds of the formula

[0634]

[0635] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0636] In some embodiments, the present invention relates to the compound 2-(4-tert-butyl-2-fluoro-3,6-dimethyl-phenyl)-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0637] In some embodiments, the present invention relates to compounds of the formula

[0638]

[0639] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0640] In some embodiments, the present invention relates to the compound 2-(4-tert-butyl-2,5-dimethyl-phenyl)-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0641] In some embodiments, the present invention relates to compounds of the formula

[0642]

[0643] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0644] In some embodiments, the present invention relates to the compound 2-[2,5-dimethyl-4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0645] In some embodiments, the present invention relates to compounds of the formula

[0646]

[0647] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0648] In some embodiments, the present invention relates to the compound 4-oxo-2-(1,1,7-trimethyltetrahydronaphthalen-6-yl)-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0649] In some embodiments, the present invention relates to compounds of the formula

[0650]

[0651] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0652] In some embodiments, the present invention relates to the compound 2-[4-isopropyl-2-methyl-5-(trifluoromethyl)phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0653] In some embodiments, the present invention relates to a compound selected from the group consisting of:

[0654]

[0655]

[0656] or a pharmaceutically acceptable salt thereof.

[0657] In some embodiments, the present invention relates to compounds of the formula

[0658]

[0659] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0660] In some embodiments, the present invention relates to the compound 2-(4-(tert-butyl)-3-chloro-2-fluoro-6-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0661] In some embodiments, the present invention relates to compounds of the formula

[0662]

[0663] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0664] In some embodiments, the present invention relates to the compound 2-(5-chloro-4-cyclobutyl-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0665] In some embodiments, the present invention relates to compounds of the formula

[0666]

[0667] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0668] In some embodiments, the present invention relates to the compound 2-(5-chloro-2-methyl-4-(1-methylcyclopropyl)phenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0669] In some embodiments, the present invention relates to compounds of the formula

[0670]

[0671] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0672] In some embodiments, the present invention relates to the compound 2-(4-(bicyclo[1.1.1]pentan-1-yl)-5-chloro-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0673] In some embodiments, the present invention relates to compounds of the formula

[0674]

[0675] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0676] In some embodiments, the present invention relates to the compound 2-(4-(tert-butyl)-3,5-difluoro-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0677] In some embodiments, the present invention relates to compounds of the formula

[0678]

[0679] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0680] In some embodiments, the present invention relates to the compound 2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0681] In some embodiments, the present invention relates to compounds of the formula

[0682]

[0683] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0684] In some embodiments, the present invention relates to the compound (R)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0685] In some embodiments, the present invention relates to compounds of the formula

[0686]

[0687] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0688] In some embodiments, the present invention relates to compound (S)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0689] In some embodiments, the present invention relates to the compound rel-(R)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide. In some embodiments, the present invention relates to the compound rel-(R)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide, wherein the compound has a stereochemistry corresponding to the first eluting isomer when the two diastereoisomers rel-(R)-4-benzyloxy-2-[5-chloro-6-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-3-pyridinyl]-1,6-naphthyridine-5-carbonitrile and rel-(S)-4-benzyloxy-2-[5-chloro-6-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-3-pyridinyl]-1,6-naphthyridine-5-carbonitrile are separated by SFC as described in Example 85. In other embodiments, the present invention relates to the foregoing compounds in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0690] In some embodiments, the present invention relates to the compound rel-(S)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide. In some embodiments, the present invention relates to the compound rel-(S)-2-(5-chloro-6-(3,3-difluoro-1-methylcyclopentyl)-2-methylpyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide, wherein when the two diastereoisomers rel-(R)-4-benzyloxy-2-[5-chloro-6-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-3-pyridinyl]-1,6-naphthyridine-5-carbonitrile and rel-(S)-4-benzyloxy-2-[5-chloro-6-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-3-pyridinyl]-1,6-naphthyridine-5-carbonitrile are separated by SFC as described in Example 85, the compound has a stereochemistry corresponding to the second eluting isomer. In other embodiments, the present invention relates to the foregoing compounds in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0691] In some embodiments, the present invention relates to compounds of the formula

[0692]

[0693] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0694] In some embodiments, the present invention relates to the compound 2-(3-chloro-2-fluoro-6-methyl-4-(1,1,1-trifluoro-2-methylprop-2-yl)phenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0695] In some embodiments, the present invention relates to compounds of the formula

[0696]

[0697] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0698] In some embodiments, the present invention relates to the compound 2-(5-chloro-2-methyl-6-(3-methylbicyclo[1.1.1]pentan-1-yl)pyridin-3-yl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as this term is used herein.

[0699] In some embodiments, the present invention relates to compounds of the formula

[0700]

[0701] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0702] In some embodiments, the present invention relates to the compound 2-(4-(tert-butyl)-5-chloro-3-fluoro-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0703] In some embodiments, the present invention relates to compounds of the formula

[0704]

[0705] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0706] In some embodiments, the present invention relates to the compound 2-(4-(bicyclo[3.1.0]hex-3-yl)-5-chloro-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0707] In some embodiments, the present invention relates to compounds of the formula

[0708]

[0709] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0710] In some embodiments, the present invention relates to the compound 2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0711] In some embodiments, the present invention relates to compounds of the formula

[0712]

[0713] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0714] In some embodiments, the present invention relates to compound (S)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0715] In some embodiments, the present invention relates to compounds of the formula

[0716]

[0717] or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as that term is used herein.

[0718] In some embodiments, the present invention relates to the compound (R)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide or a pharmaceutically acceptable salt thereof. In other embodiments, the present invention relates to the aforementioned compound in non-salt form. Such compounds are considered "compounds of the present invention," as that term is used herein.

[0719] In some embodiments, the present invention relates to the compound rel-(S)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide. In some embodiments, the present invention relates to the compound rel-(S)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide, wherein when the two diastereomers rel-(S)-2-[5-chloro-4-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide and rel-(R)-2-[5-chloro-4-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide are separated by SFC as described in Example 84, the compound has a stereochemistry corresponding to the first eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0720] In some embodiments, the present invention relates to the compound rel-(R)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide. In some embodiments, the present invention relates to the compound rel-(R)-2-(5-chloro-4-(3,3-difluoro-1-methylcyclopentyl)-2-methylphenyl)-4-oxo-1,4-dihydro-1,6-naphthyridine-5-carboxamide, wherein when the two diastereomers rel-(S)-2-[5-chloro-4-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide and rel-(R)-2-[5-chloro-4-(3,3-difluoro-1-methyl-cyclopentyl)-2-methyl-phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide are separated by SFC as described in Example 84, the compound has a stereochemistry corresponding to the second eluting isomer. In other embodiments, the present invention relates to the aforementioned compounds in non-salt form. Such compounds are considered "compounds of the present invention" as this term is used herein.

[0721] Salts, compositions, uses, formulations, administration and other pharmaceutical agents

[0722] Pharmaceutically acceptable salts and compositions

[0723] As discussed herein, the present invention provides compounds and pharmaceutically acceptable salts thereof that are voltage-gated sodium channel inhibitors, and thus the compounds of the present invention and pharmaceutically acceptable salts thereof can be used to treat diseases, disorders and conditions including, but not limited to, chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., bunionectomy pain, hernia repair pain, or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or arrhythmia. Therefore, another aspect of the present invention provides pharmaceutical compositions, wherein these compositions include a compound as described herein or a pharmaceutically acceptable salt thereof and optionally include a pharmaceutically acceptable carrier, adjuvant, or vehicle. In certain embodiments, these compositions optionally further include one or more additional therapeutic agents. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0724] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals, without undue toxicity, irritation, allergic response, etc., and commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. A "pharmaceutically acceptable salt" of a compound of the invention includes any non-toxic salt that, when administered to a recipient, is capable of directly or indirectly providing a compound of the invention or its inhibitory active metabolite or residue. The salt may be in pure form, in a mixture (e.g., solution, suspension, or colloid) containing one or more other substances, or in the form of a hydrate, solvate, or cocrystal. As used herein, the term "its inhibitory active metabolite or residue" means that its metabolite or residue is also a voltage-gated sodium channel inhibitor.

[0725] Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid; or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or by using other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconate heptanoate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates, as appropriate.

[0726] As described herein, the pharmaceutically acceptable compositions of the present invention additionally include pharmaceutically acceptable carriers, adjuvants or vehicles, as used herein, including any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc., such as those suitable for the desired specific dosage form. Remington's Pharmaceutical Sciences, 16th edition, E.W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers for formulating pharmaceutically acceptable compositions and known techniques for their preparation. Unless any conventional carrier medium is incompatible with the compound of the present invention, such as by producing any undesirable biological effect or interacting with any other component of the pharmaceutically acceptable composition in other harmful ways, it is envisioned that it will be used within the scope of the present invention. Some examples of materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, sorbic acid or potassium sorbate), mixtures of saturated vegetable fatty acid partial glycerides, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, lanolin, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate. Cellulose; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffer solutions and other nontoxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants, may also be present in the composition, according to the judgment of the formulator.

[0727] In another aspect, the invention features a pharmaceutical composition including a compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0728] In another aspect, the invention features a pharmaceutical composition including a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or vehicles.

[0729] Uses of compounds, pharmaceutically acceptable salts, and compositions

[0730] In another aspect, the invention features a method of inhibiting a voltage-gated sodium channel in a subject, the method comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is Na V 1.8.

[0731] In yet another aspect, the invention features a method of treating or lessening the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain (e.g., bunionectomy pain, hernia repair pain, or abdominoplasty pain), visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, and cardiac arrhythmia in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0732] In yet another aspect, the invention features a method of treating or lessening the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, hernia repair pain, bunionectomy pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, or cardiac arrhythmia in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0733] In yet another aspect, the invention features a method of treating or lessening the severity of intestinal pain in a subject, wherein the intestinal pain comprises inflammatory bowel disease pain, Crohn's disease pain, irritable bowel syndrome, endometriosis, polycystic ovary disease, salpingitis, cervicitis, or interstitial cystitis pain, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0734] In yet another aspect, the present invention is characterized in that the neuropathic pain for treating subject or the method for alleviating its severity, methods described include applying an effective amount of the compound of the present invention, its pharmaceutically acceptable salt or its pharmaceutical composition. In some aspects, neuropathic pain includes postherpetic neuralgia, small fiber neuropathy, diabetic neuropathy or idiopathic small fiber neuropathy. In some aspects, neuropathic pain includes diabetic neuropathy (for example, diabetic peripheral neuropathy). As used herein, phrase "idiopathic small fiber neuropathy" should be understood as including any small fiber neuropathy.

[0735] In yet another aspect, the invention features a method of treating or lessening the severity of neuropathic pain in a subject, wherein the neuropathic pain includes: post-herpetic neuralgia, diabetic neuropathy, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom limb pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy-induced neuralgia, cancer chemotherapy-induced neuralgia, antiretroviral therapy-induced neuralgia, HIV-induced neuropathy; pain after spinal cord injury, spinal stenosis pain, small fiber neuropathy, idiopathic small fiber neuropathy, idiopathic sensory neuropathy, or trigeminal autonomic cephalus, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0736] In yet another aspect, the invention features a method of treating or lessening the severity of musculoskeletal pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, musculoskeletal pain includes osteoarthritis pain.

[0737] In yet another aspect, the invention features a method of treating or lessening the severity of musculoskeletal pain in a subject, wherein the musculoskeletal pain includes osteoarthritis pain, back pain, cold pain, burn pain, or dental pain, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0738] In yet another aspect, the invention features a method of treating or lessening the severity of inflammatory pain in a subject, wherein the inflammatory pain comprises rheumatoid arthritis pain, ankylosing spondylitis, or vulvodynia, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0739] In yet another aspect, the invention features a method of treating or lessening the severity of inflammatory pain in a subject, wherein the inflammatory pain includes rheumatoid arthritis pain, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0740] In yet another aspect, the invention features a method of treating or lessening the severity of idiopathic pain in a subject, wherein the idiopathic pain includes fibromyalgia, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0741] In yet another aspect, the invention features a method of treating or lessening the severity of idiopathic pain in a subject, wherein the idiopathic pain includes reflex sympathetic dystrophy pain, wherein the method comprises administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0742] In yet another aspect, the invention features a method of treating or lessening the severity of pathological cough in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0743] In yet another aspect, the invention features a method of treating acute pain in a subject or reducing its severity, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, acute pain includes acute postoperative pain.

[0744] In yet another aspect, the invention features a method of treating or lessening the severity of postoperative pain (e.g., joint replacement pain, soft tissue surgery pain, post-thoracotomy pain, post-mastectomy pain, post-hemorrhoidectomy pain, hernia repair pain, bunionectomy pain, or abdominoplasty pain) in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0745] In yet another aspect, the invention features a method of treating or lessening the severity of bunionectomy pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0746] In yet another aspect, the invention features a method of treating or lessening the severity of shoulder replacement pain or shoulder arthroscopy pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0747] In yet another aspect, the invention features a method of treating or lessening the severity of herniorrhaphy pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0748] In yet another aspect, the invention features a method of treating or lessening the severity of abdominoplasty pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0749] In yet another aspect, the invention features a method of treating or lessening the severity of visceral pain in a subject, the method comprising administering an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, visceral pain includes visceral pain induced by abdominoplasty.

[0750] In yet another aspect, the present invention is characterized in that a method for treating a neurodegenerative disease in a subject or alleviating its severity comprises administering an effective amount of a compound of the present invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some aspects, neurodegenerative diseases include multiple sclerosis. In some aspects, neurodegenerative diseases include Pitt Hopkins Syndrome (PTHS).

[0751] In yet another aspect, the invention features methods in which a subject is treated with one or more additional therapeutic agents that are administered concurrently with, prior to, or after treatment with an effective amount of the compound, pharmaceutically acceptable salt, or pharmaceutical composition. In some embodiments, the additional therapeutic agent is a sodium channel inhibitor.

[0752] In another aspect, the invention features a method of inhibiting a voltage-gated sodium channel in a biological sample, the method comprising contacting the biological sample with an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In another aspect, the voltage-gated sodium channel is Na V 1.8.

[0753] In another aspect, the invention features treating acute pain, subacute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociplastic pain, arthritis, migraine, cluster headache, tension headache and all other forms of headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, epilepsy, epileptic conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmias, movement disorders, neuroendocrine disorders, ataxia, central neuropathic pain of multiple scleros...

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: X 5a N, N + -O - or N + -CH3; X 9a N or CR 9a ; R 3a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 4a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; Y is X 2b N or CR 2b ; X 3b N or CR 3b ; X 4b N or CR 4b ; X 5b N or CR 5b ; X 6b N or CR 6b ; Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C( O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 7b is a C1-C6 alkyl group; R 9b is a C1-C6 alkyl group; R 10b is H or halogen; Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH; The conditions are: (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than three of them are H; and (ii) If Y is X 3b is N, and X 6b CR 6b , then R 2b , R 4b , R 5b and R 6b No more than three of them are H; and (iii) If Y is X 3b CR 3b , and X 6b is N, then R 2b , R 3b , R 4b and R 5b No more than three of them are H; and (iv) If X 9a is N, Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than two of are halogen; and (v) If X 9a is N, Y is X 4b CR 4b , X 5b CR 5b , and X 6b CR 6b ,but: R 4b , R 5b and R 6b No more than two of them are H; or Z is replaced by one or more R z replace.

2. The compound according to claim 1, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Y is R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; and R 4b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

3. A compound of formula (IA): or a pharmaceutically acceptable salt thereof, wherein: X 5a N or N + -O - ; X 9a N or CR 9a ; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; Y is X 2b N or CR 2b ; X 3b N or CR 3b ; X 4b N or CR 4b ; X 5b N or CR 5b ; X 6b N or CR 6b ; Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C( O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)( C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups; R 7b is a C1-C6 alkyl group; R 9b is a C1-C6 alkyl group; R 10b is H or halogen; Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH; The conditions are: (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than three of them are H; and (ii) If Y is X 3b is N, and X 6b CR 6b , then R 2b , R 4b , R 5b and R 6b No more than three of them are H; and (iii) If Y is X 3b CR 3b , and X 6b is N, then R 2b , R 3b , R 4b and R 5b No more than three of them are H; and (iv) If X 9a is N, Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than two of are halogen; and (v) If X 9a is N, Y is X 4b CR 4b , X 5b CR 5b , and X 6b CR 6b ,but: R 4b , R 5b and R 6b No more than two of them are H; or Z is replaced by one or more R z replace.

4. The compound according to claim 3, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Y is R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; and R 4b The invention relates to H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

5. A compound of formula (IB): or a pharmaceutically acceptable salt thereof, wherein: X 5a N or N + -O - ; R 3a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 4a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; Y is X 2b N or CR 2b ; X 3b N or CR 3b ; X 4b N or CR 4b ; X 5b N or CR 5b ; X 6b N or CR 6b ; Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)( C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups; R 7b is a C1-C6 alkyl group; R 9b is a C1-C6 alkyl group; R 10b is H or halogen; Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH; The conditions are: (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than three of them are H.

6. The compound according to claim 5, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Y is R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; and R 4b The invention relates to H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

7. A compound of formula (IC): or a pharmaceutically acceptable salt thereof, wherein: R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; Y is X 2b N or CR 2b ; X 3b N or CR 3b ; X 4b N or CR 4b ; X 5b N or CR 5b ; X 6b N or CR 6b ; Z is optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally replaced by one or more R z a substituted 5- to 7-membered aromatic or non-aromatic ring; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O (C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups; R 7b is a C1-C6 alkyl group; R 9b is a C1-C6 alkyl group; R 10b is H or halogen; Each R b ' are independently C1-C6 alkyl or C1-C6 haloalkyl; and R z is halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH; The conditions are: (i) If Y is X 3b CR 3b , and X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than three of them are H.

8. The compound according to claim 7, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Y is R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; and R 4b The invention relates to H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

9. A compound of formula (ID): or a pharmaceutically acceptable salt thereof, wherein: R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; X 2b N or CR 2b ; X 5b N or CR 5b ; X 6b N or CR 6b ; Z is a 5- to 7-membered aromatic or non-aromatic ring optionally containing 1 to 3 heteroatoms selected from nitrogen and oxygen and optionally substituted by one or more R z replace; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C2-C6 alkyl), -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C2-C6 alkyl), C1-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups; and R z It is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 haloalkenyl, -CN, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2 or -C(O)OH.

10. The compound according to claim 9, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; and R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

11. A compound of formula (IE): or a pharmaceutically acceptable salt thereof, wherein: X 5a N or N + -O - ; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; X 3b N or CR 3b ; X 6b N or CR 6b ; R 2b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 3b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl), -C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or a 4- to 10-membered heterocyclic group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; R 5b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), -C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; R 6b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; and Each R b 'are independently C1-C6 alkyl or C1-C6 haloalkyl, The condition is that if X 3b CR 3b And X 6b CR 6b , then R 2b , R 3b , R 4b , R 5b and R 6b No more than three of them are H.

12. The compound according to claim 11, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 2b is H, halo, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkyl), C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; and R 4b The invention relates to H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

13. A compound of formula (IF): or a pharmaceutically acceptable salt thereof, wherein: X 5a N, N + -O - or N + -CH3; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; X 3b N or CH; R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), - C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen groups; R 4b The alkyl radicals are halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 The cycloalkyl group is optionally substituted with one or more halogen groups and the heterocyclyl group is optionally substituted with 1 to 2 R b 'replace; R 5b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; and Each R b ' is independently C1-C6 alkyl or C1-C6 haloalkyl.

14. The compound according to claim 13, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; and R 4b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

15. A compound of formula (IG): or a pharmaceutically acceptable salt thereof, wherein: X 5a N or N + -O - ; R 6a is H, halogen, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2, -O(C1-C6 C6 alkyl)-(C1-C6 alkyl), -O(C1-C6 alkyl)-NH2, -O(C1-C6 alkyl)-NH(C1-C6 alkyl), -O(C1-C6 alkyl)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2, or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; R 9a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; Each R a ' is independently halo, -OH, C1-C6 alkyl, C1-C6 haloalkyl, -C(O)O(C1-C6 alkyl) or -C(O)NH2; X 3b N or CH; R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein The cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups; R 4b The alkyl radicals are halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 haloalkyl), -C(O)(O)(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; and Each R b ' is independently C1-C6 alkyl or C1-C6 haloalkyl.

16. The compound according to claim 15, wherein: R 6a is H, halo, -CN, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C4 alkoxy, C1-C6 haloalkoxy, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -(C1-C6 alkylene)-NH2, -(C1-C6 alkylene)-NH(C1-C6 alkyl), -(C1-C6 alkylene)-N(C1-C6 alkyl)2 -C1-C6 alkyl)2, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-NH2, -O(C1-C6 alkylene)-NH(C1-C6 alkyl), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)(C1-C6 alkyl), -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), or -C(S)NH2; R 2b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C -Si(C1-C6 alkyl)3, C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halo groups; and R 4b is halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -C(O)(C1-C6 alkyl), -C(O)(C1-C6 alkoxy C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups.

17. A compound according to any one of claims 1 to 16, wherein X 5a is N.

18. A compound according to any one of claims 1 to 16, wherein X 5a N + -O - .

19. A compound according to any one of claims 1 to 16, wherein X 5a N + -CH3.

20. A compound according to any one of claims 1 to 19, wherein X 9a CR 9a And R 9a It is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, -C(O)OH or -C(O)O(C1-C6 alkyl).

21. The compound according to claim 20, wherein R 9a It is H, Cl, Br, -CH3, -OCH3, -OCH2CH3, -C(O)OH or -C(O)OCH3.

22. A compound according to any one of claims 1 to 21, wherein X 9a CR 9a And R 9a It is H, halogen, C1-C6 alkyl or C1-C6 alkoxy.

23. The compound according to claim 22, wherein R 9a It is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3.

24. A compound according to any one of claims 1 to 23, wherein R 3a It is H or C1-C6 alkyl.

25. The compound according to any one of claims 24, wherein R 3a It is H or -CH3.

26. A compound according to any one of claims 1 to 23, wherein R 3a For H.

27. A compound according to any one of claims 1 to 26, wherein R 4a For H.

28. A compound according to any one of claims 1 to 27, wherein R 6a is H, -CN, C1-C6 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; and Each R a ' is independently Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2.

29. The compound according to claim 28, wherein R 6a For H, -CN, -OCH3, -OCH2CH2CH(CH3)2, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OC H2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2, 30. A compound according to any one of claims 1 to 27, wherein R 6a It is H, -CN, C1-C6 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2.

31. The compound according to claim 30, wherein R 6a It is H, -CN, -OCH3, -OCH2CH2CH(CH3)2, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3 or -C(S)NH2.

32. A compound according to any one of claims 1 to 31, wherein Y is 33. A compound according to any one of claims 1 to 31, wherein Y is 34. A compound according to claim 32 or 33, wherein Y is 35. The compound according to claim 34, wherein X 3b is N.

36. The compound according to claim 34, wherein X 3b CR 3b And R 3b is H, halo, C1-C6 alkyl or C1-C6 haloalkyl.

37. The compound according to claim 36, wherein R 3b It is H, F, -CH3 or -CF3.

38. The compound according to claim 34, wherein X 3b CR 3b And R 3b It is H, C1-C6 alkyl or C1-C6 haloalkyl.

39. The compound according to claim 38, wherein R 3b It is H, -CH3 or -CF3.

40. A compound according to any one of claims 34 to 39, wherein X 6b is N.

41. A compound according to any one of claims 34 to 39, wherein X 6b CR 6b And R 6b It is H, halogen or C1-C6 alkyl.

42. The compound according to claim 41, wherein R 6b It is H, F or -CH3.

43. A compound according to any one of claims 34 to 42, wherein R 2b It is H, halo, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl).

44. The compound according to claim 43, wherein R 2b It is H, F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3.

45. A compound according to any one of claims 34 to 42, wherein R 2b It is H, halogen, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH.

46. ​​The compound according to claim 45, wherein R 2b It is H, F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH.

47. A compound according to any one of claims 34 to 46, wherein R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -C(O)O(C1-C6 alkyl), -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; and Each R b ' is independently -CH3 or -CF3.

48. The compound according to claim 47, wherein R 4b is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CHF2), -C(CH3)2(CF3) , -CH2C(CH3)2F, -C(=CH2)(CF3), -CH=C(CH3)2, -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH )、-C(CH3)2(C(O)OH)、-C(CH3)(CF3)(C(O)OH)、-C(O)OCH3、-Si(CH3)3、phenyl、1-methylcyclopropyl、1-trifluoromethylcyclopropyl、cyclobutyl、1-methylcyclobutyl、3,3-difluoro-1-methylcyclobutyl、cyclopentyl、1-methylcyclopentyl、1-trifluoromethylcyclopentyl、3,3-difluoro-1-methylcyclopentyl、4,4-difluoro-1-methylcyclohexyl、 49. A compound according to any one of claims 34 to 46, wherein R 4b It is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-.

50. The compound according to claim 49, wherein R 4b It is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -C(CH3)2(C(O)OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl.

51. according to the compound described in any one of claims 34 to 50, wherein R 5b It is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl.

52. The compound according to claim 51, wherein R 5b It is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl.

53. The compound according to claim 32 or 33, wherein Y is 54. The compound according to claim 53, wherein X 2b CR 2b And R 2b It is H or C1-C6 alkyl.

55. The compound according to claim 54, wherein R 2b It is H or -CH3.

56. A compound according to any one of claims 53 to 55, wherein X 5b is N.

57. A compound according to any one of claims 53 to 55, wherein X 5b CR 5b And R 5b It is H or C1-C6 alkyl.

58. The compound according to claim 57, wherein R 5b It is H or -CH3.

59. A compound according to any one of claims 53 to 58, wherein X 6b CR 6b And R 6b It is H, C1-C6 alkyl, -OH or -N(C1-C6 alkyl)2.

60. The compound according to claim 59, wherein R 6b It is H, -CH3, -OH, -N(CH3)2, -N(CH2CH2CH2)3, -N(CH3)(CH2CH2CH2CH3), -N(CH2CH3)(CH2CH2CH2CH3) or -N(CH2CH(CH3)2).

61. according to the compound described in any one of claim 53 to 60, wherein Z is optionally substituted by one to four R z Substituted 5- to 6-membered aromatic or non-aromatic carbocyclic ring.

62. according to the compound described in any one of claims 53 to 61, wherein R z It is a C1-C6 alkyl group or a C1-C6 haloalkyl group.

63. The compound according to claim 62, wherein R z It is -CH3 or -CF3.

64. A compound according to any one of claims 53 to 63, wherein Z is:

65. The compound according to claim 32, wherein Y is 66. The compound according to claim 65, wherein R 7b It is -CH3 or -CH(CH3)2.

67. The compound according to claim 65 or 66, wherein R 9b It is -C(CH3)3.

68. A compound according to any one of claims 65 to 67, wherein R 10b is H or Cl.

69. A compound according to any one of claims 1, 2, 11 or 12, wherein X 5a is N.

70. A compound according to any one of claims 1, 2, 11 or 12, wherein X 5a N + -O - .

71. according to any one of claims 1, 2, 11, 12, 69 or 70, wherein R 6a is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)NH2, -NHC(O)NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl), -C(NH)NH2, -C(S)NH2, -SO2NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl group is optionally substituted by 1 to 2 R a 'replace; and Each R a ' is Cl, -OH, -CH3, -CH2CH3, -CF3, -C(O)OCH2CH3 or -C(O)NH2.

72. The compound according to claim 71, wherein R 6a For H, -CN, -OCH3, -NH(CH3), -N(CH3)2, -NHC(O)NH2, -NHC(O)NHCH3, -OH, -OCH2CH2OCH3, -OCH2CH2N(CH 3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3, -C(NH)NH2, -C(S)NH2, -SO2NH2, 73. A compound according to any one of claims 1, 2, 11, 12, 69 or 70, wherein R 6a It is H, -CN, C1-C4 alkoxy, -NH(C1-C6 alkyl), -OH, -O(C1-C6 alkylene)-(C1-C6 alkoxy), -O(C1-C6 alkylene)-N(C1-C6 alkyl)2, -C(O)NH2, -C(O)NH(C1-C6 alkyl), -C(O)N(C1-C6 alkyl)2, -C(O)OH, -C(O)O(C1-C6 alkyl) or -C(S)NH2.

74. The compound according to claim 73, wherein R 6a It is H, -CN, -OCH3, -NH(CH3), -OH, -OCH2CH2OCH3, -OCH2CH2N(CH3)2, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3 or -C(S)NH2.

75. according to any one of claims 1, 2, 11, 12 or 69 to 74, wherein R 9a It is H, halogen, C1-C6 alkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl).

76. The compound according to claim 75, wherein R 9a It is H, Cl, Br, -CH3, -OCH3, -OCH2CH3 or -C(O)OCH3.

77. according to any one of claims 1, 2, 11, 12 or 69 to 74, wherein R 9a It is H, halogen, C1-C6 alkyl or C1-C6 alkoxy.

78. The compound according to claim 77, wherein R 9a It is H, Cl, Br, -CH3, -OCH3 or -OCH2CH3.

79. A compound according to any one of claims 1, 2, 11, 12 or 69 to 78, wherein X 3b is N.

80. A compound according to any one of claims 1, 2, 11, 12 or 69 to 78, wherein X 3b CR 3b And R 3b is H, halo, C1-C6 alkyl or C1-C6 haloalkyl.

81. The compound according to claim 80, wherein R 3b It is H, F, -CH3 or -CF3.

82. A compound according to any one of claims 1, 2, 11, 12 or 69 to 81, wherein X 3b CR 3b And R 3b It is H, C1-C6 alkyl or C1-C6 haloalkyl.

83. The compound according to claim 82, wherein R 3b It is H, -CH3 or -CF3.

84. A compound according to any one of claims 1, 2, 11, 12 or 69 to 83, wherein X 6b is N.

85. A compound according to any one of claims 1, 2, 11, 12 or 69 to 83, wherein X 6b CR 6b And R 6b It is H, halogen or C1-C6 alkyl.

86. The compound according to claim 85, wherein R 6b It is H, F or -CH3.

87. according to any one of claims 1, 2, 11, 12 or 69 to 86, wherein R 2b It is halogen, C1-C6 alkyl, C1-C6 alkoxy, -(C1-C6 alkylene)-OH or -C(O)O(C1-C6 alkyl).

88. The compound according to claim 87, wherein R 2b It is F, Cl, -CH3, -CH2CH3, -OCH3, -CH2OH, -CH2CH2CH2OH or -C(O)OCH3.

89. according to any one of claims 1, 2, 11, 12 or 69 to 88, wherein R 2b It is halogen, C1-C6 alkyl, C1-C6 alkoxy or -(C1-C6 alkylene)-OH.

90. The compound according to claim 89, wherein R 2b It is F, Cl, -CH3, -CH2CH3, -OCH3 or -CH2CH2CH2OH.

91. according to claim 1,2,11,12 or the compound described in any one of 69 to 90, wherein R 4b is H, halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 haloalkylene)-OH, -(C1-C6 alkylene)-C(O)OH, -(C1-C6 haloalkylene)-C(O)OH, -Si(C1-C6 alkyl)3, C1-C 10 Aryl, C3-C 10 Cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or a 4- to 10-membered heterocyclic group containing 1 to 3 heteroatoms selected from nitrogen and oxygen, wherein the C3-C 10 The cycloalkyl in cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen groups and the heterocyclic group is optionally substituted by 1 to 2 R b 'replace; and Each R b ' is independently -CH3 or -CF3.

92. The compound according to claim 91, wherein R 4b It is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CH=C(CH3)2, -CF3, -C(CH3)2(CHF2), - C(CH3)2(CF3), -CH2C(CH3)2F, -C(=CH2)(CF3), -OCF3, -C(CH3)2(CH2OH), -C(CH3)(CF3)(CH2OH )、-C(CH3)2(C(O)OH)、-C(CH3)(CF3)(C(O)OH)、-C(O)OCH3、-Si(CH3)3、phenyl、1-methylcyclopropyl、1-trifluoromethylcyclopropyl、cyclobutyl、1-methylcyclobutyl、3,3-difluoro-1-methylcyclobutyl、cyclopentyl、1-methylcyclopentyl、1-trifluoromethylcyclopentyl、3,3-difluoro-1-methylcyclopentyl、4,4-difluoro-1-methylcyclohexyl、 93. according to claim 1,2,11,12 or the compound described in any one of 69 to 92, wherein R 4b It is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, -(C1-C6 alkylene)-OH, -Si(C1-C6 alkyl)3 or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-.

94. The compound according to claim 93, wherein R 4b It is H, Cl, -CH3, -CH(CH3)2, -C(CH3)3, -C(CH3)2(CH2CH3), -CF3, -C(CH3)2(CF3), -C(=CH2)(CF3), -C(CH3)2(CH2OH), -Si(CH3)3 or 1-trifluoromethylcyclopropyl.

95. according to claim 1,2,11,12 or the compound described in any one of 69 to 94, wherein R 5b It is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl.

96. The compound according to claim 95, wherein R 5b It is H, F, Cl, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -OCH3 or cyclopropyl.

97. A compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein: R 3c is H, halogen or C1-C6 alkyl; R 4c is H, halogen, -CN or C1-C6 alkoxy; R 5c is H, halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or -C(O)O(C1-C6 alkyl); R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen; R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl); Y is X 3d N or CR 3d ; R 2d , R 3d and R 4d The definition is as follows: (i)R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH; R 3d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy; and R 4d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or (ii) R 2d and R 3d Together with the carbon atoms to which they are attached, they form a ring of the formula: and R 4d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or (iii) R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH; and R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula: R 5d is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or -C(O)(C1-C6 alkyl); R 6d is H, halogen or C1-C6 alkyl; R 7d is a C1-C6 alkyl group; and R 9d is a C1-C6 alkyl group; The conditions are: (i) If Y' is And X 3d CR 3d , then R 2d , R 3d , R 4d , R 5d and R 6d No more than four of them are H; and (ii) If Y' is And X 3d is N, then R 2d , R 4d , R 5d and R 6d No more than three of them are H.

98. The compound of claim 97, wherein: R 6c is H, halo, -OH, -CN, C1-C6 alkoxy or C(O)NH2; and Y is 99. A compound of formula (II-A): or a pharmaceutically acceptable salt thereof, wherein: R 3c is H, halogen or C1-C6 alkyl; R 4c is H, halogen, -CN or C1-C6 alkoxy; R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy; R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen; R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl); X 3d N or CR 3d ; R 2d , R 3d and R 4d The definition is as follows: (i)R 2d is H, halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy; R 3d is H or halo; and R 4d is H, chlorine, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; or (ii) R 2d is H, halo, -OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or -(C1-C6 alkylene)-OH; and R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula: R 5d is H, halo, C1-C6 alkyl or C1-C6 haloalkyl; and R 6d is H, halogen or C1-C6 alkyl, The conditions are: (i) If X 3d is N, then R 2d , R 4d , R 5d and R 6d No more than two of them are H; and (ii) If R 3d and R 4d Together with the carbon atoms to which they are attached, they form a ring of the formula: Then R 2d , R 5d and R 6d No more than two of them are H; and (iii) If R 4d is H, then R 2d is a C1-C6 alkyl group and R 5d is C1-C6 alkyl or C1-C6 haloalkyl; and (iv) If R 4d is chlorine, then R 2d is -OH or C1-C6 alkyl; and (v) If R 4d is -CH3, then R 2d is -OH, C1-C6 alkyl or C1-C2 alkoxy; and (vi) If R 4d is -C(CH3)3, then R 2d is H, chlorine, -OH, C1-C6 alkyl or C1-C6 alkoxy; and (vii) If R 4d is -CF3, then R 2d is C1-C6 alkyl or C1-C6 alkoxy; and (viii) If R 4d is -OCH3, then R 2d is halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy; and R 5d is halo, C1-C6 alkyl or C1-C6 haloalkyl; and (ix) If R 4d is -OC(CH3)3, then R 2d , R 3d , R 5d and R 6d No more than three of them are H; (x) If R 4d For -OCF3, then R 2d is halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy; and (xi) If R 4d is cyclopropyl, then R 2d is H, chlorine, -OH, C1-C6 alkyl or C1-C6 alkoxy; and R 6d is H or C1-C6 alkyl; and (xii) If R 2d is -OCH3 and R 4d is -CH3, then R 5d It is halogen, C1-C6 alkyl or C1-C6 haloalkyl.

100. The compound according to claim 99, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

101. A compound of formula (II-B): or a pharmaceutically acceptable salt thereof, wherein: R 3c is H, halogen or C1-C6 alkyl; R 4c is H, halogen, -CN or C1-C6 alkoxy; R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy; R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen; R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl); X 3d N or CH; R 2d is halogen, -OH, C1-C6 alkyl or C1-C6 alkoxy; R 4d is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and R 5d is a halogen group, a C1-C6 alkyl group or a C1-C6 haloalkyl group, The conditions are: (i) If R 2d is chlorine, then X 3d is N; and (ii) If R 4d is -CH3 and R 5d is -CH3, then R 2d It is -OH, C1-C6 alkyl or C1-C2 alkoxy.

102. The compound according to claim 101, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

103. A compound of formula (II-C): or a pharmaceutically acceptable salt thereof, wherein: R 3c is H, halogen or C1-C6 alkyl; R 4c is H, halogen, -CN or C1-C6 alkoxy; R 5c is H, halogen, -CN, C1-C6 alkyl or C1-C6 alkoxy; R 6c is H, halo, -OH, -CN, C1-C6 alkoxy, C(O)NH2 or a 5- to 10-membered heteroaryl group comprising 1 to 3 heteroatoms selected from nitrogen and oxygen; R 9c is H, C1-C6 alkyl, -(C1-C6 alkylene)-OH, -(C1-C6 alkylene)-O(C1-C6 alkyl), or -C(O)O(C1-C6 alkyl); X 3d N or CH; R 2d is -OH, C1-C6 alkyl or C1-C6 alkoxy; and R 4d is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; The conditions are: (i) If R 2d If -OH is 4d is a halogen group, a C1-C6 alkyl group, a C1-C6 haloalkenyl group, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and (ii) If R 2d is -CH3, then R 4d is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-, or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted with one or more halogen or -CN; and (iii) If R 2d is -OCH3, then R 4d It is C2-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkenyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -(C1-C6 alkylene)-(C1-C6 alkoxy), -Si(C1-C6 alkyl)3, -C(O)O(C1-C6 alkyl), (C1-C6 alkyl)-(C3-C6 cycloalkyl)-, (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- or C3-C6 cycloalkyl, wherein the cycloalkyl in the C3-C6 cycloalkyl, (C1-C6 alkyl)-(C3-C6 cycloalkyl)- or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)- is optionally substituted by one or more halogen or -CN.

104. The compound according to claim 350, wherein R 6c It is H, halogen, -OH, -CN, C1-C6 alkoxy or C(O)NH2.

105. A compound of formula (III): or a pharmaceutically acceptable salt thereof, wherein: X 3k N or CH; X 4k N or CH; X 5k N or CR 5k ; X 6k N, N + -O - or CR 6k ; R 5k is H, C1-C6 alkoxy, -OH, -OCH2CH2N(CH3)2 or -N(CH3)(CH2CH2OCH3); R 6k is H, -OH, C1-C6 alkoxy or -C(O)NH2; R 2L is a C1-C6 alkyl group; R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-; and R 5L is H, halogen or C1-C6 alkyl, The conditions are: (i)X 3k , X 4k and X 5k At least one of them is N, or X 6k N or N + -O - ;and (ii)X 3k , X 4k , X 5k and X 6k No more than two of them are N; and (iii) If X 6k N + -O - , then X 3k and X 4k is CH, and X 5k CR 5k ;and (iv) If X 5k is N, then X 4k is N.

106. The compound according to claim 362, wherein R 6k It is H, -OH or C1-C6 alkoxy.

107. A compound of formula (III-A): or a pharmaceutically acceptable salt thereof, wherein: X 3k N or CH; X 4k N or CH; X 5k N or CR 5k ; X 6k N, N + -O - or CR 6k ; R 5k is H, C1-C6 alkoxy, -OH or -OCH2CH2N(CH3)2; R 6k is H, -OH, C1-C6 alkoxy or -C(O)NH2; R 2L is a C1-C6 alkyl group; R 4L is C1-C6 alkyl, C1-C6 haloalkyl or (C1-C6 haloalkyl)-(C3-C6 cycloalkyl)-; and R 5L is H, halogen or C1-C6 alkyl, The conditions are: (i)X 3k , X 4k , X 5k and X 6k No more than two of them are N; and (ii) If X 6k N + -O - , then X 3k and X 4k is CH, and X 5k CR 5k ; and (iii) If X 5k is N, then X 4k is N.

108. The compound according to claim 377, wherein R 6k It is H, -OH or C1-C6 alkoxy.

109. A compound selected from Table A, or a pharmaceutically acceptable salt thereof.

110. A compound selected from Table B, or a pharmaceutically acceptable salt thereof.

111. A compound selected from: or a pharmaceutically acceptable salt thereof.

112. A compound according to any one of claims 1 to 111 in non-salt form.

113. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof or a compound according to claim 112 and one or more pharmaceutically acceptable carriers or vehicles.

114. A pharmaceutical composition comprising a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof or a compound according to claim 112 and one or more pharmaceutically acceptable carriers or vehicles.

115. A method of inhibiting a voltage-gated sodium channel in a subject, the method comprising administering to the subject a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof, a compound according to claim 112, or a pharmaceutical composition according to claim 113 or 114.

116. The method of claim 115, wherein the voltage-gated sodium channel is Na V 1.

8.

117. A method for treating or reducing the severity of chronic pain, intestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof, a compound according to claim 112, or a pharmaceutical composition according to claim 113 or 114.

118. The method of claim 117, wherein the method comprises treating or reducing the severity of neuropathic pain in the subject.

119. The method of claim 117, wherein the method comprises treating or reducing the severity of acute pain in the subject.

120. The method of any one of claims 117 to 119, wherein the subject is treated with one or more additional therapeutic agents that are administered concurrently with, prior to, or subsequent to treatment with the compound, pharmaceutically acceptable salt, or pharmaceutical composition.

121. Use of a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof, a compound according to claim 112, or a pharmaceutical composition according to claim 113 or 114 as a medicament.

122. Use of a compound according to any one of claims 1 to 111 or a pharmaceutically acceptable salt thereof, a compound according to claim 112, or a pharmaceutical composition according to claim 113 or 114 in the manufacture of a medicament for treating pain.

Images